@DRUG$ is the first @DRUG$ to be approved for clinical use, and has been studied extensively in humans since 1986. 	0
It is structurally distinct from the other currently available @DRUG$ (@DRUG$, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	0
It is structurally distinct from the other currently available @DRUG$ (lovastatin, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	0
It is structurally distinct from the other currently available @DRUG$ (lovastatin, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class. 	0
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 	0
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class. 	0
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, @DRUG$, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class. 	0
@DRUG$, an anionic-binding resin, has a considerable effect in lowering the rate and extent of @DRUG$ bioavailability. 	1
Although this effect was noted even when @DRUG$ was given 4 hours prior to @DRUG$, this regimen did not result in diminished efficacy. 	4
Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and fluvastatin. 	0
Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of warfarin and @DRUG$. 	0
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and @DRUG$. 	0
Moreover, additional interaction studies with @DRUG$ and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	0
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	0
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	0
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data. 	0
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	0
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	0
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data. 	0
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data. 	0
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data. 	0
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data. 	0
These would include a variety of preparations which contain @DRUG$, @DRUG$, progestins, or glucocorticoids.	0
These would include a variety of preparations which contain @DRUG$, estrogens, @DRUG$, or glucocorticoids.	0
These would include a variety of preparations which contain @DRUG$, estrogens, progestins, or @DRUG$.	0
These would include a variety of preparations which contain androgens, @DRUG$, @DRUG$, or glucocorticoids.	0
These would include a variety of preparations which contain androgens, @DRUG$, progestins, or @DRUG$.	0
These would include a variety of preparations which contain androgens, estrogens, @DRUG$, or @DRUG$.	0
The gonadotropin levels may be transiently elevated by @DRUG$, minimally elevated by @DRUG$, and suppressed by oral contraceptives and digoxin.	0
The gonadotropin levels may be transiently elevated by @DRUG$, minimally elevated by levodopa, and suppressed by oral @DRUG$ and digoxin.	0
The gonadotropin levels may be transiently elevated by @DRUG$, minimally elevated by levodopa, and suppressed by oral contraceptives and @DRUG$.	0
The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by @DRUG$, and suppressed by oral @DRUG$ and digoxin.	0
The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by @DRUG$, and suppressed by oral contraceptives and @DRUG$.	0
The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral @DRUG$ and @DRUG$.	0
The response to @DRUG$ may be blunted by @DRUG$ and dopamine antagonists which cause a rise in prolactin.	4
The response to @DRUG$ may be blunted by phenothiazines and @DRUG$ which cause a rise in prolactin.	4
The response to Factrel may be blunted by @DRUG$ and @DRUG$ which cause a rise in prolactin.	0
The mode of toxic action of the pesticide @DRUG$: the metabolism of @DRUG$ to (-)-erythro-fluorocitrate.  	0
The mode of toxic action of the pesticide @DRUG$: the metabolism of 1,3-difluoroacetone to @DRUG$.  	0
The mode of toxic action of the pesticide gliftor: the metabolism of @DRUG$ to @DRUG$.  	0
The biochemical toxicology of @DRUG$, a known metabolite of the major ingredient of the pesticide @DRUG$ (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. 	0
The biochemical toxicology of @DRUG$, a known metabolite of the major ingredient of the pesticide Gliftor (@DRUG$), was investigated in vivo and in vitro. 	0
The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide @DRUG$ (@DRUG$), was investigated in vivo and in vitro. 	0
Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted @DRUG$ to @DRUG$ in vitro. 	0
Administration of @DRUG$ (100 mg kg(-1) body weight) to rats in vivo resulted in @DRUG$ synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation. 	0
Animals dosed with @DRUG$ did not display the 2-3 hour lag phase in either @DRUG$ synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. 	0
Animals dosed with @DRUG$ did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with @DRUG$. 	0
Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either @DRUG$ synthesis or in citrate and fluoride accumulation characteristic of animals dosed with @DRUG$. 	0
We demonstrate that the conversion of @DRUG$ to @DRUG$ by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 	0
We demonstrate that the conversion of @DRUG$ to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, @DRUG$ from 1,3-difluoro-2-propanol. 	0
We demonstrate that the conversion of @DRUG$ to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from @DRUG$. 	0
We demonstrate that the conversion of 1,3-difluoro-2-propanol to @DRUG$ by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, @DRUG$ from 1,3-difluoro-2-propanol. 	0
We demonstrate that the conversion of 1,3-difluoro-2-propanol to @DRUG$ by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from @DRUG$. 	0
We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, @DRUG$ from @DRUG$. 	0
Prior administration of @DRUG$ (90 mg kg(-1) body weight) was shown to prevent the conversion of @DRUG$ (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	4
Prior administration of @DRUG$ (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to @DRUG$ in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	0
Prior administration of @DRUG$ (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in @DRUG$-intoxicated animals. 	0
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of @DRUG$ (100 mg kg(-1) body weight) to @DRUG$ in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 	0
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of @DRUG$ (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in @DRUG$-intoxicated animals. 	0
Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to @DRUG$ in vivo and to eliminate the fluoride and citrate elevations seen in @DRUG$-intoxicated animals. 	0
However, administration of @DRUG$ (90 mg kg(-1) body weight) to rats 2 hours prior to @DRUG$ (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. 	0
However, administration of @DRUG$ (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing @DRUG$ synthesis and did not diminish fluoride or citrate accumulation in vivo. 	0
However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to @DRUG$ (100 mg kg(-1) body weight) was ineffective in preventing @DRUG$ synthesis and did not diminish fluoride or citrate accumulation in vivo. 	0
We conclude that the prophylactic and antidotal properties of @DRUG$ seen in animals treated with @DRUG$ derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.	4
We conclude that the prophylactic and antidotal properties of @DRUG$ seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting @DRUG$ to 1,3-difluoroacetone in the committed step of the toxic pathway.	0
We conclude that the prophylactic and antidotal properties of @DRUG$ seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to @DRUG$ in the committed step of the toxic pathway.	0
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with @DRUG$ derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting @DRUG$ to 1,3-difluoroacetone in the committed step of the toxic pathway.	0
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with @DRUG$ derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to @DRUG$ in the committed step of the toxic pathway.	0
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting @DRUG$ to @DRUG$ in the committed step of the toxic pathway.	0
Pharmacokinetic interaction between single oral doses of @DRUG$ and @DRUG$ in healthy volunteers.  	1
AIM AND BACKGROUND: The pharmacokinetic interaction between @DRUG$, a @DRUG$ metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 	0
AIM AND BACKGROUND: The pharmacokinetic interaction between @DRUG$, a macrolide immunosuppressant metabolized by CYP3A4, and the @DRUG$ diltiazem was studied in 18 healthy subjects. 	0
AIM AND BACKGROUND: The pharmacokinetic interaction between @DRUG$, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker @DRUG$ was studied in 18 healthy subjects. 	0
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a @DRUG$ metabolized by CYP3A4, and the @DRUG$ diltiazem was studied in 18 healthy subjects. 	0
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a @DRUG$ metabolized by CYP3A4, and the calcium channel blocker @DRUG$ was studied in 18 healthy subjects. 	0
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the @DRUG$ @DRUG$ was studied in 18 healthy subjects. 	0
Several clinically important interactions have previously been reported for other @DRUG$ that are metabolized by the same enzyme and for @DRUG$. 	0
METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of @DRUG$, a single oral 120-mg dose of @DRUG$, and the two drugs given together. 	0
RESULTS: The geometric mean (90% confidence interval) whole blood @DRUG$ area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with @DRUG$ coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. 	1
RESULTS: The geometric mean (90% confidence interval) whole blood @DRUG$ area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of @DRUG$ decreased slightly, from 79 to 67 hours. 	0
RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with @DRUG$ coadministration, whereas the mean elimination half-life of @DRUG$ decreased slightly, from 79 to 67 hours. 	0
Apparent oral clearance and volume of distribution of @DRUG$ decreased with 38% and 45%, respectively, when @DRUG$ was given with diltiazem. 	0
Apparent oral clearance and volume of distribution of @DRUG$ decreased with 38% and 45%, respectively, when sirolimus was given with @DRUG$. 	0
Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when @DRUG$ was given with @DRUG$. 	1
The plasma maximum concentration and area under the plasma concentration-time curve of @DRUG$, @DRUG$, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	0
The plasma maximum concentration and area under the plasma concentration-time curve of @DRUG$, desacetyldiltiazem, and @DRUG$ were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	0
The plasma maximum concentration and area under the plasma concentration-time curve of @DRUG$, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of @DRUG$, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	0
The plasma maximum concentration and area under the plasma concentration-time curve of @DRUG$, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of @DRUG$ on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	0
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, @DRUG$, and @DRUG$ were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	0
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, @DRUG$, and desmethyldiltiazem were unchanged after coadministration of @DRUG$, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	0
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, @DRUG$, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of @DRUG$ on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	0
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and @DRUG$ were unchanged after coadministration of @DRUG$, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	0
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and @DRUG$ were unchanged after coadministration of sirolimus, and no potentiation of the effects of @DRUG$ on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	0
The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of @DRUG$, and no potentiation of the effects of @DRUG$ on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 	0
CONCLUSIONS: Single-dose @DRUG$ coadministration leads to higher @DRUG$ exposure, presumably by inhibition of the first-pass metabolism of sirolimus. 	1
CONCLUSIONS: Single-dose @DRUG$ coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of @DRUG$. 	0
CONCLUSIONS: Single-dose diltiazem coadministration leads to higher @DRUG$ exposure, presumably by inhibition of the first-pass metabolism of @DRUG$. 	0
Because of the pronounced intersubject variability in the extent of the @DRUG$-@DRUG$ interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.	3
Because of the pronounced intersubject variability in the extent of the @DRUG$-diltiazem interaction, whole blood @DRUG$ concentrations should be monitored closely in patients treated with the two drugs.	0
Because of the pronounced intersubject variability in the extent of the sirolimus-@DRUG$ interaction, whole blood @DRUG$ concentrations should be monitored closely in patients treated with the two drugs.	0
Preliminary data which suggest that @DRUG$ may inhibit the anti-inflammatory activity of @DRUG$ have not been confirmed.	4
If leprosy-associated inflammatory reactions develop in patients being treated with @DRUG$ and @DRUG$, it is still advisable to continue treatment with both drugs.	3
@DRUG$ augments the action of @DRUG$s and the muscle relaxant effects of aminoglycosides.	4
@DRUG$ augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of @DRUG$.	4
FLUOTHANE augments the action of @DRUG$s and the muscle relaxant effects of @DRUG$.	0
@DRUG$ may augment the hypotension caused by the ganglionic-blocking effect of @DRUG$.	4
Caution should be exercised during the administration of @DRUG$ to patients anaesthetised with @DRUG$ as arrhythmias may be precipitated.	3
For this reason the dose of @DRUG$ should be restricted and an @DRUG$ administered as appropriate.	0
Caution should also be applied for other @DRUG$, and for @DRUG$ and theophylline and tricyclic antidepressants, which may also precipitate arrhythmias.	0
Caution should also be applied for other @DRUG$, and for aminophylline and @DRUG$ and tricyclic antidepressants, which may also precipitate arrhythmias.	0
Caution should also be applied for other @DRUG$, and for aminophylline and theophylline and @DRUG$, which may also precipitate arrhythmias.	0
Caution should also be applied for other sympathomimetics, and for @DRUG$ and @DRUG$ and tricyclic antidepressants, which may also precipitate arrhythmias.	0
Caution should also be applied for other sympathomimetics, and for @DRUG$ and theophylline and @DRUG$, which may also precipitate arrhythmias.	0
Caution should also be applied for other sympathomimetics, and for aminophylline and @DRUG$ and @DRUG$, which may also precipitate arrhythmias.	0
@DRUG$: @DRUG$ has been studied in rheumatoid arthritis patients taking concomitant MTX.	0
@DRUG$: HUMIRA has been studied in rheumatoid arthritis patients taking concomitant @DRUG$.	0
Methotrexate: @DRUG$ has been studied in rheumatoid arthritis patients taking concomitant @DRUG$.	0
The data do not suggest the need for dose adjustment of either @DRUG$ or @DRUG$.	0
@DRUG$: Concurrent administration of @DRUG$ (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.	0
@DRUG$: Concurrent administration of anakinra (an @DRUG$) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.	0
@DRUG$: Concurrent administration of anakinra (an interleukin-1 antagonist) and another @DRUG$ has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.	0
Anakinra: Concurrent administration of @DRUG$ (an @DRUG$) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.	0
Anakinra: Concurrent administration of @DRUG$ (an interleukin-1 antagonist) and another @DRUG$ has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.	4
Anakinra: Concurrent administration of anakinra (an @DRUG$) and another @DRUG$ has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.	4
The safety and efficacy of @DRUG$ used in combination with @DRUG$ has not been studied.	0
Therefore the, combination of @DRUG$ with other @DRUG$, including HUMIRA, may also result i n similar toxicities.	4
Therefore the, combination of @DRUG$ with other TNF-blocking agents, including @DRUG$, may also result i n similar toxicities.	4
Therefore the, combination of anakinra with other @DRUG$, including @DRUG$, may also result i n similar toxicities.	0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when @DRUG$ is administered in combination with other @DRUG$ such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.	4
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when @DRUG$ is administered in combination with other CNS depressants such as @DRUG$, tranquilizers, opioids, or inhalation general anesthetics.	4
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when @DRUG$ is administered in combination with other CNS depressants such as barbiturates, @DRUG$, opioids, or inhalation general anesthetics.	4
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when @DRUG$ is administered in combination with other CNS depressants such as barbiturates, tranquilizers, @DRUG$, or inhalation general anesthetics.	4
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when @DRUG$ is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general @DRUG$.	4
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other @DRUG$ such as @DRUG$, tranquilizers, opioids, or inhalation general anesthetics.	0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other @DRUG$ such as barbiturates, @DRUG$, opioids, or inhalation general anesthetics.	0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other @DRUG$ such as barbiturates, tranquilizers, @DRUG$, or inhalation general anesthetics.	0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other @DRUG$ such as barbiturates, tranquilizers, opioids, or inhalation general @DRUG$.	0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as @DRUG$, @DRUG$, opioids, or inhalation general anesthetics.	0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as @DRUG$, tranquilizers, @DRUG$, or inhalation general anesthetics.	0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as @DRUG$, tranquilizers, opioids, or inhalation general @DRUG$.	0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, @DRUG$, @DRUG$, or inhalation general anesthetics.	0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, @DRUG$, opioids, or inhalation general @DRUG$.	0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, @DRUG$, or inhalation general @DRUG$.	0
Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	1
Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of @DRUG$ with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	0
Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with @DRUG$ can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	0
Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.	0
Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of @DRUG$ with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	0
Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of erythromycin with @DRUG$ can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	0
Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of erythromycin with ALFENTA can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.	0
Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of @DRUG$ with @DRUG$ can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	1
Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of @DRUG$ with ALFENTA can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.	0
Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with @DRUG$ can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.	0
@DRUG$ reduces the clearance of @DRUG$.	1
Therefore smaller @DRUG$ doses will be required with prolonged administration and the duration of action of @DRUG$ my be extended.	0
@DRUG$ has been found to temporarily raise serum concentrations of @DRUG$.	1
@DRUG$ may potentiate the adverse effects of other @DRUG$ administered concomitantly.	4
In particular, convulsions have been reported when @DRUG$ is administered with @DRUG$ and special care should be taken when the treatment regimen includes both of these drugs.	4
Because @DRUG$ is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of @DRUG$.	0
Patients who have been treated with @DRUG$ within two to three weeks prior to the administration of @DRUG$ should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.	3
Patients who have been treated with @DRUG$ within two to three weeks prior to the administration of dopamine HCl should receive initial doses of @DRUG$ no greater than one-tenth (1/10) of the usual dose.	0
Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of @DRUG$ should receive initial doses of @DRUG$ no greater than one-tenth (1/10) of the usual dose.	0
Concurrent administration of low-dose @DRUG$ and @DRUG$ may produce an additive or potentiating effect on urine flow.	4
Cardiac effects of @DRUG$ are antagonized by @DRUG$, such as propranolol and metoprolol.	4
Cardiac effects of @DRUG$ are antagonized by beta-adrenergic blocking agents, such as @DRUG$ and metoprolol.	4
Cardiac effects of @DRUG$ are antagonized by beta-adrenergic blocking agents, such as propranolol and @DRUG$.	4
Cardiac effects of dopamine are antagonized by @DRUG$, such as @DRUG$ and metoprolol.	0
Cardiac effects of dopamine are antagonized by @DRUG$, such as propranolol and @DRUG$.	0
Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as @DRUG$ and @DRUG$.	0
The peripheral vasoconstriction caused by high doses of @DRUG$ is antagonized by @DRUG$.	4
@DRUG$-induced renal and mesenteric vasodilation is not antagonized by either @DRUG$.	0
@DRUG$-induced renal and mesenteric vasodilation is not antagonized by either alpha- or @DRUG$.	0
Dopamine-induced renal and mesenteric vasodilation is not antagonized by either @DRUG-DRUG$.	0
@DRUG$ (such as @DRUG$) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.	0
@DRUG$ (such as haloperidol) and @DRUG$ can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.	0
@DRUG$ (such as haloperidol) and phenothiazines can suppress the @DRUG$rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.	4
Butyrophenones (such as @DRUG$) and @DRUG$ can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.	0
Butyrophenones (such as @DRUG$) and phenothiazines can suppress the @DRUG$rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.	4
Butyrophenones (such as haloperidol) and @DRUG$ can suppress the @DRUG$rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.	4
@DRUG$ or @DRUG$ increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.	0
@DRUG$ or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$, such as dopamine.	4
@DRUG$ or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as @DRUG$.	4
Cyclopropane or @DRUG$ increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$, such as dopamine.	4
Cyclopropane or @DRUG$ increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as @DRUG$.	4
Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$, such as @DRUG$.	0
Therefore, EXTREME CAUTION should be exercised when administering @DRUG$ to patients receiving @DRUG$ or halogenated hydrocarbon anesthetics.	3
Therefore, EXTREME CAUTION should be exercised when administering @DRUG$ to patients receiving cyclopropane or @DRUG$.	3
Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving @DRUG$ or @DRUG$.	0
It has been reported that results of studies in animals indicate that @DRUG$-induced ventricular arrhythmias during anesthesia can be reversed by @DRUG$.	4
The concomitant use of @DRUG$s, vasoconstricting agents (such as @DRUG$) and some oxytocic drugs may result in severe hypertension.	0
The concomitant use of @DRUG$s, vasoconstricting agents (such as ergonovine) and some @DRUG$ may result in severe hypertension.	4
The concomitant use of vasopressors, vasoconstricting agents (such as @DRUG$) and some @DRUG$ may result in severe hypertension.	4
Administration of @DRUG$ to patients receiving @DRUG$ has been reported to lead to hypotension and bradycardia.	4
It is suggested that in patients receiving @DRUG$, alternatives to @DRUG$ should be used if anticonvulsant therapy is needed.	3
It is suggested that in patients receiving @DRUG$, alternatives to phenytoin should be used if @DRUG$ therapy is needed.	0
It is suggested that in patients receiving dopamine HCl, alternatives to @DRUG$ should be used if @DRUG$ therapy is needed.	0
Elevated plasma levels of @DRUG$ have been reported with concomitant @DRUG$ use.	1
There have been reports of @DRUG$-related side effects in patients on concomitant therapy with @DRUG$ and theophylline.	0
There have been reports of @DRUG$-related side effects in patients on concomitant therapy with norfloxacin and @DRUG$.	0
There have been reports of theophylline-related side effects in patients on concomitant therapy with @DRUG$ and @DRUG$.	4
Therefore, monitoring of @DRUG$ plasma levels should be considered and dosage of @DRUG$ adjusted as required.	0
Elevated serum levels of @DRUG$ have been reported with concomitant use of @DRUG$ with norfloxacin.	0
Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with @DRUG$.	0
Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with @DRUG$.	1
Therefore, @DRUG$ serum levels should be monitored and appropriate @DRUG$ dosage adjustments made when these drugs are used concomitantly.	0
@DRUG$, including @DRUG$, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.	0
@DRUG$, including norfloxacin, may enhance the effects of oral @DRUG$, including warfarin or its derivatives or similar agents.	4
@DRUG$, including norfloxacin, may enhance the effects of oral anticoagulants, including @DRUG$ or its derivatives or similar agents.	4
Quinolones, including @DRUG$, may enhance the effects of oral @DRUG$, including warfarin or its derivatives or similar agents.	4
Quinolones, including @DRUG$, may enhance the effects of oral anticoagulants, including @DRUG$ or its derivatives or similar agents.	4
Quinolones, including norfloxacin, may enhance the effects of oral @DRUG$, including @DRUG$ or its derivatives or similar agents.	0
The concomitant administration of @DRUG$ including @DRUG$ with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.	0
The concomitant administration of @DRUG$ including norfloxacin with @DRUG$ (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.	4
The concomitant administration of @DRUG$ including norfloxacin with glyburide (a @DRUG$) has, on rare occasions, resulted in severe hypoglycemia.	0
The concomitant administration of quinolones including @DRUG$ with @DRUG$ (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.	4
The concomitant administration of quinolones including @DRUG$ with glyburide (a @DRUG$) has, on rare occasions, resulted in severe hypoglycemia.	0
The concomitant administration of quinolones including norfloxacin with @DRUG$ (a @DRUG$) has, on rare occasions, resulted in severe hypoglycemia.	0
Diminished urinary excretion of @DRUG$ has been reported during the concomitant administration of @DRUG$ and norfloxacin.	0
Diminished urinary excretion of @DRUG$ has been reported during the concomitant administration of probenecid and @DRUG$.	0
Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of @DRUG$ and @DRUG$.	1
The concomitant use of @DRUG$ is not recommended since @DRUG$ may antagonize the antibacterial effect of Norfloxacin in the urinary tract.	0
The concomitant use of @DRUG$ is not recommended since nitrofurantoin may antagonize the antibacterial effect of @DRUG$ in the urinary tract.	0
The concomitant use of nitrofurantoin is not recommended since @DRUG$ may antagonize the antibacterial effect of @DRUG$ in the urinary tract.	4
@DRUG$, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	0
@DRUG$, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	0
@DRUG$, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	0
@DRUG$, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	0
@DRUG$, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	3
@DRUG$, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	0
Multivitamins, or other products containing @DRUG$ or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	0
Multivitamins, or other products containing @DRUG$ or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	0
Multivitamins, or other products containing @DRUG$ or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	0
Multivitamins, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	3
Multivitamins, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	0
Multivitamins, or other products containing iron or @DRUG$, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	0
Multivitamins, or other products containing iron or @DRUG$, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	0
Multivitamins, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	3
Multivitamins, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	0
Multivitamins, or other products containing iron or zinc, @DRUG$ or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	0
Multivitamins, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	3
Multivitamins, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	0
Multivitamins, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	3
Multivitamins, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	0
Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	0
@DRUG$ (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	0
@DRUG$ (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	3
@DRUG$ (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	0
Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	3
Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	0
Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because these products may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	0
Some @DRUG$ have also been shown to interfere with the metabolism of @DRUG$.	1
Interactions may occur between @DRUG$ supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).	2
Interactions may occur between @DRUG$ supplements and aspirin and other @DRUG$ and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).	2
Interactions may occur between @DRUG$ supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ (Ginkgo biloba).	2
Interactions may occur between @DRUG$ supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (@DRUG$).	2
Interactions may occur between EPA supplements and @DRUG$ and other @DRUG$ and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).	0
Interactions may occur between EPA supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ (Ginkgo biloba).	0
Interactions may occur between EPA supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (@DRUG$).	0
Interactions may occur between EPA supplements and aspirin and other @DRUG$ and herbs such as garlic (Allium sativum) and @DRUG$ (Ginkgo biloba).	0
Interactions may occur between EPA supplements and aspirin and other @DRUG$ and herbs such as garlic (Allium sativum) and ginkgo (@DRUG$).	0
Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ (@DRUG$).	0
@DRUG$ (@DRUG$ ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.	0
@DRUG$ (brinzolamide ophthalmic suspension) 1% contains a @DRUG$.	0
AZOPT (@DRUG$ ophthalmic suspension) 1% contains a @DRUG$.	0
However, in patients treated with oral @DRUG$, rare instances of drug interactions have occurred with high-dose @DRUG$ therapy.	2
Therefore, the potential for such drug interaction should be considered in patients receiving @DRUG$ (@DRUG$ ophthalmic suspension) 1%.	0
@DRUG$ accelerates the metabolism of @DRUG$;	1
therefore, if @DRUG$ replacement is needed, @DRUG$ should be prescribed.	0
@DRUG$ diminishes the effect of @DRUG$ and warfarin.	4
@DRUG$ diminishes the effect of coumarin and @DRUG$.	4
Aminoglutethimide diminishes the effect of @DRUG$ and @DRUG$.	0
@DRUG$ potentiates other @DRUG$ such as succinylcholine or organophosphate and carbamate insecticides.	4
@DRUG$ potentiates other cholinesterase inhibitors such as @DRUG$ or organophosphate and carbamate insecticides.	4
@DRUG$ potentiates other cholinesterase inhibitors such as succinylcholine or @DRUG$s.	4
@DRUG$ potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and @DRUG$s.	4
Phospholine Iodide potentiates other @DRUG$ such as @DRUG$ or organophosphate and carbamate insecticides.	0
Phospholine Iodide potentiates other @DRUG$ such as succinylcholine or @DRUG$s.	0
Phospholine Iodide potentiates other @DRUG$ such as succinylcholine or organophosphate and @DRUG$s.	0
Phospholine Iodide potentiates other cholinesterase inhibitors such as @DRUG$ or @DRUG$s.	0
Phospholine Iodide potentiates other cholinesterase inhibitors such as @DRUG$ or organophosphate and @DRUG$s.	0
Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or @DRUG-DRUG$s.	0
The concomitant use of @DRUG$ or other @DRUG$ may have an additive effect.	0
Increased hepatotoxicity of @DRUG$ by concomitant administration of @DRUG$ in the rat.	4
Since @DRUG$ is frequently co-administered with @DRUG$, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 	0
Since @DRUG$ is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of @DRUG$ on the hepatotoxicity of acetaminophen. 	0
Since @DRUG$ is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of @DRUG$. 	0
Since caffeine is frequently co-administered with @DRUG$, it is of clinical interest to study the effect of @DRUG$ on the hepatotoxicity of acetaminophen. 	0
Since caffeine is frequently co-administered with @DRUG$, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of @DRUG$. 	0
Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of @DRUG$ on the hepatotoxicity of @DRUG$. 	0
Careful observations on hepatotoxicity are suggested when @DRUG$ is prescribed with @DRUG$.	4
In vitro studies demonstrated that the plasma protein binding of @DRUG$ was not affected by @DRUG$ or salicylic acid, indicating no potential for protein binding-based drug interactions.	0
In vitro studies demonstrated that the plasma protein binding of @DRUG$ was not affected by warfarin or @DRUG$, indicating no potential for protein binding-based drug interactions.	0
In vitro studies demonstrated that the plasma protein binding of des-ciclesonide was not affected by @DRUG$ or @DRUG$, indicating no potential for protein binding-based drug interactions.	0
In a drug interaction study, co-administration of orally inhaled @DRUG$ and oral @DRUG$, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin.	0
In a drug interaction study, co-administration of orally inhaled @DRUG$ and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either @DRUG$ or erythromycin.	0
In a drug interaction study, co-administration of orally inhaled @DRUG$ and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or @DRUG$.	0
In a drug interaction study, co-administration of orally inhaled ciclesonide and oral @DRUG$, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either @DRUG$ or erythromycin.	0
In a drug interaction study, co-administration of orally inhaled ciclesonide and oral @DRUG$, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or @DRUG$.	0
In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either @DRUG$ or @DRUG$.	0
In another drug interaction study, co-administration of orally inhaled @DRUG$ and oral @DRUG$, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.	1
In another drug interaction study, co-administration of orally inhaled @DRUG$ and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of @DRUG$ by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.	0
In another drug interaction study, co-administration of orally inhaled @DRUG$ and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of @DRUG$ remained unchanged.	0
In another drug interaction study, co-administration of orally inhaled ciclesonide and oral @DRUG$, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of @DRUG$ by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.	0
In another drug interaction study, co-administration of orally inhaled ciclesonide and oral @DRUG$, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of @DRUG$ remained unchanged.	0
In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of @DRUG$ by approximately 3.6-fold at steady state, while levels of @DRUG$ remained unchanged.	0
Therefore, @DRUG$ should be administered with caution with intranasal @DRUG$.	3
The @DRUG$ (@DRUG$)-induced diarrhea was analyzed in cecectomized rats prepared by resecting the cecum and its vasculature without disturbing the ileocecal junction. 	0
On the other hand, the enhanced secretion of colonic fluid by @DRUG$, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of @DRUG$ in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration. 	0
@DRUG$ and @DRUG$ (0.1 and 1.0 mg/kg, s.c.) 	0
@DRUG$ and @DRUG$ (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	0
@DRUG$ and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the @DRUG$ (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	4
Loperamide and @DRUG$ (0.1 and 1.0 mg/kg, s.c.) inhibited the @DRUG$ (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 	4
@DRUG$ (5 mg/kg, s.c.) completely antagonized the inhibitory effect of @DRUG$ and partly antagonized the effect of morphine. 	4
@DRUG$ (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of @DRUG$. 	4
N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of @DRUG$ and partly antagonized the effect of @DRUG$. 	0
No drugs are known to interfere with the conversion of @DRUG$ to @DRUG$.	0
Conversion could be affected by alterations in the level of phosphatase activity, but given the abundance and wide distribution of phosphatases in the body it is unlikely that drugs would affect this activity enough to affect conversion of @DRUG$ to @DRUG$.	0
The pharmacokinetics and protein binding of @DRUG$, @DRUG$, and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.	0
The pharmacokinetics and protein binding of @DRUG$, phenytoin, and @DRUG$ were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.	0
The pharmacokinetics and protein binding of @DRUG$, phenytoin, and diazepam were not altered when @DRUG$ and Cerebyx were concurrently administered in single submaximal doses.	0
The pharmacokinetics and protein binding of @DRUG$, phenytoin, and diazepam were not altered when diazepam and @DRUG$ were concurrently administered in single submaximal doses.	0
The pharmacokinetics and protein binding of fosphenytoin, @DRUG$, and @DRUG$ were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.	0
The pharmacokinetics and protein binding of fosphenytoin, @DRUG$, and diazepam were not altered when @DRUG$ and Cerebyx were concurrently administered in single submaximal doses.	0
The pharmacokinetics and protein binding of fosphenytoin, @DRUG$, and diazepam were not altered when diazepam and @DRUG$ were concurrently administered in single submaximal doses.	0
The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and @DRUG$ were not altered when @DRUG$ and Cerebyx were concurrently administered in single submaximal doses.	0
The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and @DRUG$ were not altered when diazepam and @DRUG$ were concurrently administered in single submaximal doses.	0
The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when @DRUG$ and @DRUG$ were concurrently administered in single submaximal doses.	0
The most significant drug interactions following administration of @DRUG$ are expected to occur with drugs that interact with @DRUG$.	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma @DRUG$ concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	1
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute @DRUG$ intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, @DRUG$, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, @DRUG$, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, @DRUG$, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, @DRUG$, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, @DRUG$, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, @DRUG$, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, @DRUG$, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, @DRUG$, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, @DRUG$, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, @DRUG$, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, @DRUG$, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, @DRUG$, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, @DRUG$, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, @DRUG$, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, @DRUG$, succinimides, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, @DRUG$, salicylates, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, @DRUG$, sulfonamides, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, @DRUG$, succinimides, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, @DRUG$, tolbutamide, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, @DRUG$, sulfonamides, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, @DRUG$, trazodone	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, @DRUG$, tolbutamide, @DRUG$	0
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, @DRUG$, @DRUG$	0
- Drugs that may decrease plasma @DRUG$ concentrations include: @DRUG$, chronic alcohol abuse, reserpine	1
- Drugs that may decrease plasma @DRUG$ concentrations include: carbamazepine, chronic @DRUG$ abuse, reserpine	1
- Drugs that may decrease plasma @DRUG$ concentrations include: carbamazepine, chronic alcohol abuse, @DRUG$	1
- Drugs that may decrease plasma phenytoin concentrations include: @DRUG$, chronic @DRUG$ abuse, reserpine	0
- Drugs that may decrease plasma phenytoin concentrations include: @DRUG$, chronic alcohol abuse, @DRUG$	0
- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic @DRUG$ abuse, @DRUG$	0
- Drugs that may either increase or decrease plasma @DRUG$ concentrations include: @DRUG$, vaiproic acid, and sodium valproate.	1
- Drugs that may either increase or decrease plasma @DRUG$ concentrations include: phenobarbital, vaiproic acid, and @DRUG$.	1
- Drugs that may either increase or decrease plasma phenytoin concentrations include: @DRUG$, vaiproic acid, and @DRUG$.	0
Similarly, the effects of @DRUG$ on @DRUG$, valproic acid and sodium plasma valproate concentrations are unpredictable	4
Similarly, the effects of @DRUG$ on phenobarbital, @DRUG$ and sodium plasma valproate concentrations are unpredictable	4
Similarly, the effects of @DRUG$ on phenobarbital, valproic acid and sodium plasma @DRUG$ concentrations are unpredictable	4
Similarly, the effects of phenytoin on @DRUG$, @DRUG$ and sodium plasma valproate concentrations are unpredictable	0
Similarly, the effects of phenytoin on @DRUG$, valproic acid and sodium plasma @DRUG$ concentrations are unpredictable	0
Similarly, the effects of phenytoin on phenobarbital, @DRUG$ and sodium plasma @DRUG$ concentrations are unpredictable	0
- Although not a true drug interaction, @DRUG$ may precipitate seizures in susceptible patients and @DRUG$ dosage may need to be adjusted	4
- Drugs whose efficacy is impaired by @DRUG$ include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	4
- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	4
- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	4
- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	4
- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	4
- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	4
- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	4
- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	4
- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	4
- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	4
- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	4
- Drugs whose efficacy is impaired by @DRUG$ include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	4
- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: @DRUG$, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, @DRUG$, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, @DRUG$, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, @DRUG$, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, @DRUG$, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, @DRUG$, furosemide, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral @DRUG$, rifampin, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, @DRUG$, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, @DRUG$, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, @DRUG$, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, @DRUG$, oral contraceptives, rifampin, quinidine, theophylline, @DRUG$.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, @DRUG$, quinidine, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, @DRUG$, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, @DRUG$, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral @DRUG$, rifampin, quinidine, theophylline, @DRUG$.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, @DRUG$, theophylline, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, @DRUG$, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, @DRUG$, quinidine, theophylline, @DRUG$.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, @DRUG$, vitamin D.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, @DRUG$, theophylline, @DRUG$.	0
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, @DRUG$, @DRUG$.	0
Care should be taken when using immunoanalytical methods to measure plasma @DRUG$ concentrations following @DRUG$ administration.	0
A possible drug interaction of @DRUG$ and intravenous @DRUG$ has been described.	2
Concomitant treatment of four patients in the United Kingdom with @DRUG$ and intravenous @DRUG$ may have caused hypocalcemia;	4
Because of @DRUG$s tendency to cause renal impairment, the use of @DRUG$ should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.	0
Because of @DRUG$s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as @DRUG$, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.	0
Because of @DRUG$s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, @DRUG$ and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.	0
Because of @DRUG$s tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous @DRUG$ unless the potential benefits outweigh the risks to the patient.	0
Because of foscarnets tendency to cause renal impairment, the use of @DRUG$ should be avoided in combination with potentially nephrotoxic drugs such as @DRUG$, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.	3
Because of foscarnets tendency to cause renal impairment, the use of @DRUG$ should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, @DRUG$ and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.	3
Because of foscarnets tendency to cause renal impairment, the use of @DRUG$ should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous @DRUG$ unless the potential benefits outweigh the risks to the patient.	3
Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as @DRUG$, @DRUG$ and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.	0
Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as @DRUG$, amphotericin B and intravenous @DRUG$ unless the potential benefits outweigh the risks to the patient.	0
Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, @DRUG$ and intravenous @DRUG$ unless the potential benefits outweigh the risks to the patient.	0
@DRUG$: The pharmacokinetics of @DRUG$ and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.	0
@DRUG$: The pharmacokinetics of foscarnet and @DRUG$ were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.	0
Ganciclovir: The pharmacokinetics of @DRUG$ and @DRUG$ were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.	0
The vasodilating effects of @DRUG$ may be additive with those of other @DRUG$.	4
Marked symptomatic orthostatic hypotension has been reported when @DRUG$ and @DRUG$ were used in combination.	4
If taken 1 hour before @DRUG$ (@DRUG$), didanosine does not affect IDV exposure, despite persistent buffering effects.  	0
If taken 1 hour before @DRUG$ (IDV), @DRUG$ does not affect IDV exposure, despite persistent buffering effects.  	0
If taken 1 hour before @DRUG$ (IDV), didanosine does not affect @DRUG$ exposure, despite persistent buffering effects.  	0
If taken 1 hour before indinavir (@DRUG$), @DRUG$ does not affect IDV exposure, despite persistent buffering effects.  	0
If taken 1 hour before indinavir (@DRUG$), didanosine does not affect @DRUG$ exposure, despite persistent buffering effects.  	0
If taken 1 hour before indinavir (IDV), @DRUG$ does not affect @DRUG$ exposure, despite persistent buffering effects.  	0
Concurrent administration of @DRUG$ and @DRUG$ significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 	1
Concurrent administration of @DRUG$ and didanosine significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after didanosine administration indinavir may be given safely. 	0
Concurrent administration of @DRUG$ and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after @DRUG$ administration indinavir may be given safely. 	0
Concurrent administration of @DRUG$ and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration @DRUG$ may be given safely. 	0
Concurrent administration of indinavir and @DRUG$ significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after didanosine administration indinavir may be given safely. 	0
Concurrent administration of indinavir and @DRUG$ significantly reduces the level of exposure to indinavir, but it is unclear how soon after @DRUG$ administration indinavir may be given safely. 	0
Concurrent administration of indinavir and @DRUG$ significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration @DRUG$ may be given safely. 	0
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after @DRUG$ administration indinavir may be given safely. 	0
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after didanosine administration @DRUG$ may be given safely. 	0
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after @DRUG$ administration @DRUG$ may be given safely. 	0
We compared @DRUG$ pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of @DRUG$ alone versus 800 mg of indinavir administered 1 h after didanosine administration. 	0
We compared @DRUG$ pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of @DRUG$ administered 1 h after didanosine administration. 	0
We compared @DRUG$ pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after @DRUG$ administration. 	0
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of @DRUG$ alone versus 800 mg of @DRUG$ administered 1 h after didanosine administration. 	0
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of @DRUG$ alone versus 800 mg of indinavir administered 1 h after @DRUG$ administration. 	0
We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of @DRUG$ administered 1 h after @DRUG$ administration. 	0
Median gastric pH was significantly higher when @DRUG$ was taken after @DRUG$ administration; 	1
@DRUG$ may be taken with a light meal 1 h following the administration of 400 mg of @DRUG$.	3
This drug may interact with @DRUG$ or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	0
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	0
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	0
Coadministration of @DRUG$ and drugs primarily metabolized by CYP3A (e.g., @DRUG$) may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects.	0
Coadministration of @DRUG$ and drugs that induce CYP3A may decrease @DRUG$ plasma concentrations and reduce its therapeutic effect.	0
Coadministration of @DRUG$ and drugs that inhibit CYP3A may increase @DRUG$ plasma concentrations.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or @DRUG$.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or @DRUG$.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/@DRUG$, clarithromycin, erythromycin, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or @DRUG$.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, @DRUG$, erythromycin, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, @DRUG$, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, erythromycin, @DRUG$ or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or @DRUG$.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, @DRUG$, itraconazole or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, @DRUG$ or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or @DRUG$.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, @DRUG$ or fluconazole.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or @DRUG$.	0
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or @DRUG$.	0
Drugs That Should Not Be Coadministered With @DRUG$ @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	3
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	3
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	3
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	3
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	3
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	3
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	3
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	3
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	3
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	3
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	3
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	3
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	3
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ @DRUG$ midazolam, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ @DRUG$, triazolam GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, @DRUG$ GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: @DRUG$	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, @DRUG$ GI motility agents: cisapride	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: @DRUG$	0
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: @DRUG$	0
Drugs Which Require a Dose Reduction When Coadminstered With @DRUG$ @DRUG$: rifabutin	3
Drugs Which Require a Dose Reduction When Coadminstered With @DRUG$ Antimycobacterial agents: @DRUG$	3
Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT @DRUG$: @DRUG$	0
* This table is not all inclusive ** @DRUG$ may not be effective due to decreased @DRUG$ plasma concentrations in patients taking these agents concomitantly	0
@DRUG$: Administration of @DRUG$ with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;	0
@DRUG$: Administration of terfenadine with @DRUG$ resulted in the appearance of unchanged terfenadine in plasma;	0
@DRUG$: Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged @DRUG$ in plasma;	0
Terfenadine: Administration of @DRUG$ with @DRUG$ resulted in the appearance of unchanged terfenadine in plasma;	0
Terfenadine: Administration of @DRUG$ with VIRACEPT resulted in the appearance of unchanged @DRUG$ in plasma;	0
Terfenadine: Administration of terfenadine with @DRUG$ resulted in the appearance of unchanged @DRUG$ in plasma;	0
therefore, @DRUG$ should not be administered concurrently with @DRUG$ because of the potential for serious and/or life-threatening cardiac arrhythmias.	3
Because a similar interaction is likely, @DRUG$ should also not be administered concurrently with @DRUG$.	3
@DRUG$: Coadministration of @DRUG$ with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.	0
@DRUG$: Coadministration of indinavir with @DRUG$ resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.	0
@DRUG$: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in indinavir plasma A.C.	0
@DRUG$: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in @DRUG$ plasma A.C.	0
Indinavir: Coadministration of @DRUG$ with @DRUG$ resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.	1
Indinavir: Coadministration of @DRUG$ with VIRACEPT resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in indinavir plasma A.C.	0
Indinavir: Coadministration of @DRUG$ with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in @DRUG$ plasma A.C.	0
Indinavir: Coadministration of indinavir with @DRUG$ resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in indinavir plasma A.C.	0
Indinavir: Coadministration of indinavir with @DRUG$ resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in @DRUG$ plasma A.C.	0
Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in @DRUG$ plasma A.C.	0
@DRUG$: Coadministration of @DRUG$ with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.	0
@DRUG$: Coadministration of ritonavir with @DRUG$ resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.	0
@DRUG$: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in @DRUG$ plasma AUC and very little change in ritonavir plasma A.C.	0
@DRUG$: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in @DRUG$ plasma A.C.	0
Ritonavir: Coadministration of @DRUG$ with @DRUG$ resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.	1
Ritonavir: Coadministration of @DRUG$ with VIRACEPT resulted in a 152% increase in @DRUG$ plasma AUC and very little change in ritonavir plasma A.C.	0
Ritonavir: Coadministration of @DRUG$ with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in @DRUG$ plasma A.C.	0
Ritonavir: Coadministration of ritonavir with @DRUG$ resulted in a 152% increase in @DRUG$ plasma AUC and very little change in ritonavir plasma A.C.	0
Ritonavir: Coadministration of ritonavir with @DRUG$ resulted in a 152% increase in nelfinavir plasma AUC and very little change in @DRUG$ plasma A.C.	0
Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in @DRUG$ plasma AUC and very little change in @DRUG$ plasma A.C.	0
@DRUG$: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	0
@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	0
@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	0
@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	0
@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	0
Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	0
Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	1
Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	0
Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	0
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	0
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	0
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	0
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	0
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	0
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	0
@DRUG$: Coadministration of @DRUG$ with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.	0
@DRUG$: Coadministration of ketoconazole with @DRUG$ resulted in a 35% increase in nelfinavir plasma A.C.	0
@DRUG$: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in @DRUG$ plasma A.C.	0
Ketoconazole: Coadministration of @DRUG$ with @DRUG$ resulted in a 35% increase in nelfinavir plasma A.C.	1
Ketoconazole: Coadministration of @DRUG$ with VIRACEPT resulted in a 35% increase in @DRUG$ plasma A.C.	0
Ketoconazole: Coadministration of ketoconazole with @DRUG$ resulted in a 35% increase in @DRUG$ plasma A.C.	0
This change was not considered clinically significant and no dose adjustment is needed when @DRUG$ and @DRUG$ are coadministered.	0
@DRUG$: It is recommended that @DRUG$ be administered on an empty stomach;	0
therefore, @DRUG$ should be administered (with food) one hour after or more than two hours before @DRUG$.	3
A dose adjustment is not needed when @DRUG$ is administered with @DRUG$.	3
Little or no change in the pharmacokinetics of either drug was observed when @DRUG$ was coadministered with @DRUG$ or stavudine.	0
Little or no change in the pharmacokinetics of either drug was observed when @DRUG$ was coadministered with lamivudine or @DRUG$.	0
Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with @DRUG$ or @DRUG$.	0
@DRUG$: Coadministration of @DRUG$ and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.	0
@DRUG$: Coadministration of rifabutin and @DRUG$ resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.	0
@DRUG$: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in rifabutin plasma A.C.	0
@DRUG$: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in @DRUG$ plasma A.C.	0
Rifabutin: Coadministration of @DRUG$ and @DRUG$ resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.	1
Rifabutin: Coadministration of @DRUG$ and VIRACEPT resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in rifabutin plasma A.C.	0
Rifabutin: Coadministration of @DRUG$ and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in @DRUG$ plasma A.C.	0
Rifabutin: Coadministration of rifabutin and @DRUG$ resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in rifabutin plasma A.C.	0
Rifabutin: Coadministration of rifabutin and @DRUG$ resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in @DRUG$ plasma A.C.	0
Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in @DRUG$ plasma A.C.	0
It is recommended that the dose of @DRUG$ be reduced to one-half the usual dose when administered with @DRUG$.	3
@DRUG$: Coadministration of @DRUG$ and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.	0
@DRUG$: Coadministration of rifampin and @DRUG$ resulted in an 82% decrease in nelfinavir plasma A.C.	0
@DRUG$: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in @DRUG$ plasma A.C.	0
Rifampin: Coadministration of @DRUG$ and @DRUG$ resulted in an 82% decrease in nelfinavir plasma A.C.	1
Rifampin: Coadministration of @DRUG$ and VIRACEPT resulted in an 82% decrease in @DRUG$ plasma A.C.	0
Rifampin: Coadministration of rifampin and @DRUG$ resulted in an 82% decrease in @DRUG$ plasma A.C.	0
@DRUG$ and @DRUG$ should not be coadministered.	3
@DRUG$ and @DRUG$: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	0
@DRUG$ and Norethindrone: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	0
@DRUG$ and Norethindrone: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	0
@DRUG$ and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	0
@DRUG$ and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	0
Ethinyl Estradiol and @DRUG$: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	0
Ethinyl Estradiol and @DRUG$: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	0
Ethinyl Estradiol and @DRUG$: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	0
Ethinyl Estradiol and @DRUG$: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	0
Ethinyl Estradiol and Norethindrone: Coadministration of @DRUG$ with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	1
Ethinyl Estradiol and Norethindrone: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	0
Ethinyl Estradiol and Norethindrone: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	0
Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	0
Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	0
Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in @DRUG$ plasma concentrations.	0
@DRUG$ is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered @DRUG$.	0
@DRUG$: In a single (400 mg) and multiple dose (400 mg TID) study of @DRUG$ in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.	0
@DRUG$: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on @DRUG$ monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.	0
@DRUG$: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, @DRUG$ had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.	0
@DRUG$: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of @DRUG$ and phenytoin had no effect on gabapentin pharmacokinetics.	0
@DRUG$: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and @DRUG$ had no effect on gabapentin pharmacokinetics.	0
@DRUG$: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on @DRUG$ pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of @DRUG$ in epileptic patients (N=8) maintained on @DRUG$ monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of @DRUG$ in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, @DRUG$ had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of @DRUG$ in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of @DRUG$ and phenytoin had no effect on gabapentin pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of @DRUG$ in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and @DRUG$ had no effect on gabapentin pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of @DRUG$ in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on @DRUG$ pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on @DRUG$ monotherapy for at least 2 months, @DRUG$ had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on @DRUG$ monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of @DRUG$ and phenytoin had no effect on gabapentin pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on @DRUG$ monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and @DRUG$ had no effect on gabapentin pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on @DRUG$ monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on @DRUG$ pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, @DRUG$ had no effect on the steady-state trough plasma concentrations of @DRUG$ and phenytoin had no effect on gabapentin pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, @DRUG$ had no effect on the steady-state trough plasma concentrations of phenytoin and @DRUG$ had no effect on gabapentin pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, @DRUG$ had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on @DRUG$ pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of @DRUG$ and @DRUG$ had no effect on gabapentin pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of @DRUG$ and phenytoin had no effect on @DRUG$ pharmacokinetics.	0
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and @DRUG$ had no effect on @DRUG$ pharmacokinetics.	0
@DRUG$: Steady-state trough plasma @DRUG$ and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant gabapentin (400 mg TID;	0
@DRUG$: Steady-state trough plasma carbamazepine and @DRUG$ concentrations were not affected by concomitant gabapentin (400 mg TID;	0
@DRUG$: Steady-state trough plasma carbamazepine and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant @DRUG$ (400 mg TID;	0
Carbamazepine: Steady-state trough plasma @DRUG$ and @DRUG$ concentrations were not affected by concomitant gabapentin (400 mg TID;	0
Carbamazepine: Steady-state trough plasma @DRUG$ and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant @DRUG$ (400 mg TID;	0
Carbamazepine: Steady-state trough plasma carbamazepine and @DRUG$ concentrations were not affected by concomitant @DRUG$ (400 mg TID;	0
Likewise, @DRUG$ pharmacokinetics were unaltered by @DRUG$ administration.	0
@DRUG$: The mean steady-state trough serum @DRUG$ concentrations prior to and during concomitant gabapentin administration (400 mg TID;	0
@DRUG$: The mean steady-state trough serum valproic acid concentrations prior to and during concomitant @DRUG$ administration (400 mg TID;	0
Valproic Acid: The mean steady-state trough serum @DRUG$ concentrations prior to and during concomitant @DRUG$ administration (400 mg TID;	0
N=17) were not different and neither were @DRUG$ pharmacokinetic parameters affected by @DRUG$.	0
@DRUG$: Estimates of steady-state pharmacokinetic parameters for @DRUG$ or gabapentin (300 mg TID;	0
@DRUG$: Estimates of steady-state pharmacokinetic parameters for phenobarbital or @DRUG$ (300 mg TID;	0
Phenobarbital: Estimates of steady-state pharmacokinetic parameters for @DRUG$ or @DRUG$ (300 mg TID;	0
@DRUG$: Coadministration (N=18) of @DRUG$ capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.	0
@DRUG$: Coadministration (N=18) of naproxen sodium capsules (250 mg) with @DRUG$ (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.	0
@DRUG$: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of @DRUG$ absorbed by 12% to 15%.	0
Naproxen: Coadministration (N=18) of @DRUG$ capsules (250 mg) with @DRUG$ (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.	1
Naproxen: Coadministration (N=18) of @DRUG$ capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of @DRUG$ absorbed by 12% to 15%.	0
Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with @DRUG$ (125 mg) appears to increase the amount of @DRUG$ absorbed by 12% to 15%.	0
@DRUG$ had no effect on @DRUG$ pharmacokinetic parameters.	0
@DRUG$: Coadministration of @DRUG$  (125 to 500 mg;	0
Cmax and AUC values are 3% to 4% lower, respectively, after administration of 125 mg @DRUG$  and 21% to 22% lower, respectively, after administration of 500 mg @DRUG$ .	0
@DRUG$ increases @DRUG$ AUC values by 14%.	1
@DRUG$: A literature article reported that when a 60-mg controlled-release @DRUG$ capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.	0
@DRUG$: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg @DRUG$  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.	0
@DRUG$: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean @DRUG$ AUC increased by 44% compared to gabapentin administered without morphine.	0
@DRUG$: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to @DRUG$ administered without morphine.	0
@DRUG$: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without @DRUG$.	0
Morphine: A literature article reported that when a 60-mg controlled-release @DRUG$ capsule was administered 2 hours prior to a 600-mg @DRUG$  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.	1
Morphine: A literature article reported that when a 60-mg controlled-release @DRUG$ capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean @DRUG$ AUC increased by 44% compared to gabapentin administered without morphine.	0
Morphine: A literature article reported that when a 60-mg controlled-release @DRUG$ capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to @DRUG$ administered without morphine.	0
Morphine: A literature article reported that when a 60-mg controlled-release @DRUG$ capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without @DRUG$.	0
Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg @DRUG$  capsule (N=12), mean @DRUG$ AUC increased by 44% compared to gabapentin administered without morphine.	0
Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg @DRUG$  capsule (N=12), mean gabapentin AUC increased by 44% compared to @DRUG$ administered without morphine.	0
Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg @DRUG$  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without @DRUG$.	0
Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean @DRUG$ AUC increased by 44% compared to @DRUG$ administered without morphine.	0
Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean @DRUG$ AUC increased by 44% compared to gabapentin administered without @DRUG$.	0
Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to @DRUG$ administered without @DRUG$.	0
@DRUG$ pharmacokinetic parameter values were not affected by administration of @DRUG$  2 hours after morphine.	0
@DRUG$ pharmacokinetic parameter values were not affected by administration of Neurontin  2 hours after @DRUG$.	0
Morphine pharmacokinetic parameter values were not affected by administration of @DRUG$  2 hours after @DRUG$.	0
@DRUG$: In the presence of @DRUG$ at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.	0
@DRUG$: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of @DRUG$ fell by 14% and creatinine clearance fell by 10%.	0
Cimetidine: In the presence of @DRUG$ at 300 mg QID (N=12) the mean apparent oral clearance of @DRUG$ fell by 14% and creatinine clearance fell by 10%.	1
Thus @DRUG$ appeared to alter the renal excretion of both @DRUG$ and creatinine, an endogenous marker of renal function.	1
This small decrease in excretion of @DRUG$ by @DRUG$ is not expected to be of clinical importance.	1
The effect of @DRUG$ on @DRUG$ was not evaluated.	0
Oral @DRUG$: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;	0
Oral @DRUG$: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and @DRUG$ following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;	0
Oral @DRUG$: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of @DRUG$ and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;	0
Oral @DRUG$: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of @DRUG$ were similar with and without coadministration of gabapentin (400 mg TID;	0
Oral @DRUG$: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of @DRUG$ (400 mg TID;	0
Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of @DRUG$ and @DRUG$ following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;	0
Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of tablets containing 2.5 mg of @DRUG$ and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;	0
Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of @DRUG$ were similar with and without coadministration of gabapentin (400 mg TID;	0
Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of @DRUG$ and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of @DRUG$ (400 mg TID;	0
Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and @DRUG$ following administration of tablets containing 2.5 mg of @DRUG$ and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;	0
Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and @DRUG$ following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of @DRUG$ were similar with and without coadministration of gabapentin (400 mg TID;	0
Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and @DRUG$ following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of @DRUG$ (400 mg TID;	0
Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of @DRUG$ and 50 mcg of @DRUG$ were similar with and without coadministration of gabapentin (400 mg TID;	0
Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of @DRUG$ and 50 mcg of ethinyl estradiol were similar with and without coadministration of @DRUG$ (400 mg TID;	0
Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of @DRUG$ were similar with and without coadministration of @DRUG$ (400 mg TID;	0
The Cmax of @DRUG$ was 13% higher when it was coadministered with @DRUG$;	1
@DRUG$ (@DRUG$ ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.	0
@DRUG$ (Maalox ): @DRUG$ reduced the bioavailability of gabapentin (N=16) by about 20%.	0
@DRUG$ (Maalox ): Maalox reduced the bioavailability of @DRUG$ (N=16) by about 20%.	0
Antacid (@DRUG$ ): @DRUG$ reduced the bioavailability of gabapentin (N=16) by about 20%.	0
Antacid (@DRUG$ ): Maalox reduced the bioavailability of @DRUG$ (N=16) by about 20%.	0
Antacid (Maalox ): @DRUG$ reduced the bioavailability of @DRUG$ (N=16) by about 20%.	1
This decrease in bioavailability was about 5% when @DRUG$ was administered 2 hours after @DRUG$.	1
It is recommended that @DRUG$ be taken at least 2 hours following @DRUG$ administration.	3
Effect of @DRUG$: @DRUG$ is a blocker of renal tubular secretion.	0
@DRUG$ pharmacokinetic parameters without and with @DRUG$ were comparable.	0
This indicates that @DRUG$ does not undergo renal tubular secretion by the pathway that is blocked by @DRUG$.	0
Drug/Laboratory Tests Interactions Because false positive readings were reported with the Ames N-Multistix SG dipstick test for urinary protein when @DRUG$ was added to other @DRUG$, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein	0
@DRUG$: @DRUG$ may diminish adrenal suppression by corticosteroids.	0
@DRUG$: Aminoglutethimide may diminish adrenal suppression by @DRUG$.	0
Aminoglutethimide: @DRUG$ may diminish adrenal suppression by @DRUG$.	4
@DRUG$ injection and potassium-depleting agents: When @DRUG$ are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.	0
@DRUG$ injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., @DRUG$, diuretics), patients should be observed closely for development of hypokalemia.	0
@DRUG$ injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, @DRUG$), patients should be observed closely for development of hypokalemia.	0
Amphotericin B injection and potassium-depleting agents: When @DRUG$ are administered concomitantly with potassium-depleting agents (e.g., @DRUG$, diuretics), patients should be observed closely for development of hypokalemia.	3
Amphotericin B injection and potassium-depleting agents: When @DRUG$ are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, @DRUG$), patients should be observed closely for development of hypokalemia.	3
Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., @DRUG$, @DRUG$), patients should be observed closely for development of hypokalemia.	0
In addition, there have been cases reported in which concomitant use of @DRUG$ and @DRUG$ was followed by cardiac enlargement and congestive heart failure.	4
@DRUG$: @DRUG$ have been reported to cause a significant decrease in corticosteroid clearance.	0
@DRUG$: Macrolide antibiotics have been reported to cause a significant decrease in @DRUG$ clearance.	0
Antibiotics: @DRUG$ have been reported to cause a significant decrease in @DRUG$ clearance.	1
@DRUG$: Concomitant use of @DRUG$ and corticosteroids may produce severe weakness in patients with myasthenia gravis.	0
@DRUG$: Concomitant use of anticholinesterase agents and @DRUG$ may produce severe weakness in patients with myasthenia gravis.	0
Anticholinesterases: Concomitant use of @DRUG$ and @DRUG$ may produce severe weakness in patients with myasthenia gravis.	4
If possible, @DRUG$ should be withdrawn at least 24 hours before initiating @DRUG$ therapy.	3
@DRUG$, oral: Co-administration of @DRUG$ and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.	0
@DRUG$, oral: Co-administration of corticosteroids and @DRUG$ usually results in inhibition of response to warfarin, although there have been some conflicting reports.	0
@DRUG$, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to @DRUG$, although there have been some conflicting reports.	0
Anticoagulants, oral: Co-administration of @DRUG$ and @DRUG$ usually results in inhibition of response to warfarin, although there have been some conflicting reports.	4
Anticoagulants, oral: Co-administration of @DRUG$ and warfarin usually results in inhibition of response to @DRUG$, although there have been some conflicting reports.	0
Anticoagulants, oral: Co-administration of corticosteroids and @DRUG$ usually results in inhibition of response to @DRUG$, although there have been some conflicting reports.	0
@DRUG$: Because @DRUG$ may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.	0
@DRUG$: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of @DRUG$ may be required.	0
Antidiabetics: Because @DRUG$ may increase blood glucose concentrations, dosage adjustments of @DRUG$ may be required.	4
@DRUG$: @DRUG$ may increase the clearance of corticosteroids.	0
@DRUG$: Cholestyramine may increase the clearance of @DRUG$.	0
Cholestyramine: @DRUG$ may increase the clearance of @DRUG$.	1
@DRUG$: Increased activity of both @DRUG$ and corticosteroids may occur when the two are used concurrently.	0
@DRUG$: Increased activity of both cyclosporine and @DRUG$ may occur when the two are used concurrently.	0
Cyclosporine: Increased activity of both @DRUG$ and @DRUG$ may occur when the two are used concurrently.	4
@DRUG$: Patients on @DRUG$ may be at increased risk of arrhythmias due to hypokalemia.	0
@DRUG$: @DRUG$ may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.	0
@DRUG$: Ephedrine may enhance the metabolic clearance of @DRUG$, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.	0
@DRUG$: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in @DRUG$ dosage.	0
Ephedrine: @DRUG$ may enhance the metabolic clearance of @DRUG$, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.	1
Ephedrine: @DRUG$ may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in @DRUG$ dosage.	0
Ephedrine: Ephedrine may enhance the metabolic clearance of @DRUG$, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in @DRUG$ dosage.	0
@DRUG$, including oral @DRUG$: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.	0
@DRUG$, including oral contraceptives: @DRUG$ may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.	0
@DRUG$, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain @DRUG$, thereby increasing their effect.	0
Estrogens, including oral @DRUG$: @DRUG$ may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.	0
Estrogens, including oral @DRUG$: Estrogens may decrease the hepatic metabolism of certain @DRUG$, thereby increasing their effect.	0
Estrogens, including oral contraceptives: @DRUG$ may decrease the hepatic metabolism of certain @DRUG$, thereby increasing their effect.	1
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, @DRUG$, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	0
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, @DRUG$, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	0
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, carbamazepine, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	0
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, carbamazepine, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	1
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	0
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, @DRUG$, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	0
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, carbamazepine, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	0
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, carbamazepine, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	1
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	0
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, @DRUG$, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	0
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, @DRUG$, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	1
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, @DRUG$, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	0
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, @DRUG$) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	1
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	0
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the @DRUG$ be increased.	0
Drugs which inhibit CYP 3A4 (e.g., @DRUG$, @DRUG$ such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.	0
Drugs which inhibit CYP 3A4 (e.g., @DRUG$, macrolide antibiotics such as @DRUG$) have the potential to result in increased plasma concentrations of corticosteroids.	0
Drugs which inhibit CYP 3A4 (e.g., @DRUG$, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of @DRUG$.	1
Drugs which inhibit CYP 3A4 (e.g., ketoconazole, @DRUG$ such as @DRUG$) have the potential to result in increased plasma concentrations of corticosteroids.	0
Drugs which inhibit CYP 3A4 (e.g., ketoconazole, @DRUG$ such as erythromycin) have the potential to result in increased plasma concentrations of @DRUG$.	1
Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as @DRUG$) have the potential to result in increased plasma concentrations of @DRUG$.	1
Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., @DRUG$, @DRUG$) may increase their clearance, resulting in decreased plasma concentration.	0
@DRUG$: @DRUG$ has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.	0
@DRUG$: Ketoconazole has been reported to decrease the metabolism of certain @DRUG$ by up to 60%, leading to increased risk of corticosteroid side effects.	0
@DRUG$: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of @DRUG$ side effects.	0
Ketoconazole: @DRUG$ has been reported to decrease the metabolism of certain @DRUG$ by up to 60%, leading to increased risk of corticosteroid side effects.	1
Ketoconazole: @DRUG$ has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of @DRUG$ side effects.	0
Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain @DRUG$ by up to 60%, leading to increased risk of @DRUG$ side effects.	0
In addition, @DRUG$ alone can inhibit adrenal @DRUG$ synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.	4
@DRUG$ (@DRUG$): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.	0
@DRUG$ (NSAIDS): Concomitant use of @DRUG$ (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.	0
@DRUG$ (NSAIDS): Concomitant use of aspirin (or other @DRUG$) and corticosteroids increases the risk of gastrointestinal side effects.	0
@DRUG$ (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and @DRUG$ increases the risk of gastrointestinal side effects.	0
Nonsteroidal anti-inflammatory agents (@DRUG$): Concomitant use of @DRUG$ (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.	0
Nonsteroidal anti-inflammatory agents (@DRUG$): Concomitant use of aspirin (or other @DRUG$) and corticosteroids increases the risk of gastrointestinal side effects.	0
Nonsteroidal anti-inflammatory agents (@DRUG$): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and @DRUG$ increases the risk of gastrointestinal side effects.	0
Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of @DRUG$ (or other @DRUG$) and corticosteroids increases the risk of gastrointestinal side effects.	0
Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of @DRUG$ (or other nonsteroidal antiinflammatory agents) and @DRUG$ increases the risk of gastrointestinal side effects.	4
Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other @DRUG$) and @DRUG$ increases the risk of gastrointestinal side effects.	4
@DRUG$ should be used cautiously in conjunction with @DRUG$ in hypoprothrombinemia.	3
The clearance of @DRUG$ may be increased with concurrent use of @DRUG$.	1
@DRUG$: In post-marketing experience, there have been reports of both increases and decreases in @DRUG$ levels with dexamethasone co-administration, leading to alterations in seizure control.	0
@DRUG$: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with @DRUG$ co-administration, leading to alterations in seizure control.	0
Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in @DRUG$ levels with @DRUG$ co-administration, leading to alterations in seizure control.	1
@DRUG$: Co-administration with @DRUG$ should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.	0
@DRUG$: Patients on @DRUG$ therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.	0
@DRUG$: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and @DRUG$ due to inhibition of antibody response.	0
@DRUG$: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or @DRUG$ due to inhibition of antibody response.	0
Vaccines: Patients on @DRUG$ therapy may exhibit a diminished response to toxoids and @DRUG$ due to inhibition of antibody response.	4
Vaccines: Patients on @DRUG$ therapy may exhibit a diminished response to toxoids and live or @DRUG$ due to inhibition of antibody response.	4
Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and @DRUG-DRUG$ due to inhibition of antibody response.	0
@DRUG$ may also potentiate the replication of some organisms contained in @DRUG$.	4
Routine administration of @DRUG$ or toxoids should be deferred until @DRUG$ therapy is discontinued if possible.	3
@DRUG$ should be used with caution in patients who are receiving a @DRUG$ orally because of the potential for additive effects on systemic beta-blockade.	3
Close observation of the patient is recommended when a @DRUG$ is administered to patients receiving catecholamine-depleting drugs such as @DRUG$, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.	3
@DRUG$ may decrease the amount of @DRUG$ (Lanoxin, Lanoxicaps) that gets absorbed into your body.	1
@DRUG$ may decrease the amount of digoxin (@DRUG$, Lanoxicaps) that gets absorbed into your body.	1
@DRUG$ may decrease the amount of digoxin (Lanoxin, @DRUG$) that gets absorbed into your body.	0
Aminosalicylic acid may decrease the amount of @DRUG$ (@DRUG$, Lanoxicaps) that gets absorbed into your body.	0
Aminosalicylic acid may decrease the amount of @DRUG$ (Lanoxin, @DRUG$) that gets absorbed into your body.	0
Aminosalicylic acid may decrease the amount of digoxin (@DRUG$, @DRUG$) that gets absorbed into your body.	0
In the case that you are taking @DRUG$ while taking @DRUG$, higher doses of digoxin may be needed.	3
In the case that you are taking @DRUG$ while taking aminosalicylic acid, higher doses of @DRUG$ may be needed.	0
In the case that you are taking digoxin while taking @DRUG$, higher doses of @DRUG$ may be needed.	0
@DRUG$ may also decrease the absorption of @DRUG$, which can lead to a deficiency.	1
Therefore you may need to take a @DRUG$ supplement while taking @DRUG$.	3
Careful observation is required when @DRUG$ is administered concurrently with @DRUG$.	3
For information on the pharmacokinetics of @DRUG$ and @DRUG$ in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.	0
The in vitro interaction between @DRUG$ and the @DRUG$ warfarin is complex.	0
The in vitro interaction between @DRUG$ and the antithrombotic agent @DRUG$ is complex.	2
The in vitro interaction between nevirapine and the @DRUG$ @DRUG$ is complex.	0
When @DRUG$ is co-administered with @DRUG$, anticoagulation levels should be monitored frequently.	3
@DRUG$ exposure was significantly decreased by @DRUG$;	1
Alternatives to @DRUG$,such as @DRUG$, should be considered.	0
@DRUG$ and @DRUG$	0
@DRUG$ @DRUG$	0
Oral @DRUG$ and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking @DRUG$, since nevirapinemay lower the plasma levels of thesemedications.	3
@DRUG$ and @DRUG$ should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.	3
@DRUG$ and ketoconazole should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy of the drug.	0
Nevirapine and @DRUG$ should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy of the drug.	0
@DRUG$/@DRUG$	0
A dose increase of @DRUG$/@DRUG$ to 533/133 mg twice daily with food isrecommended in combination with nevirapine.	0
A dose increase of @DRUG$/ritonavir to 533/133 mg twice daily with food isrecommended in combination with @DRUG$.	3
A dose increase of lopinavir/@DRUG$ to 533/133 mg twice daily with food isrecommended in combination with @DRUG$.	3
@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	0
@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. @DRUG$ maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	0
@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	0
@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.	0
Methadone levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. @DRUG$ maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	0
Methadone levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. Methadone maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	0
Methadone levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.	0
Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. @DRUG$ maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	3
Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. @DRUG$ maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.	0
Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.	0
The appropriate dose for @DRUG$ incombination with @DRUG$, with respectto safety and efficacy, has not been established.	0
@DRUG$ and @DRUG$ should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.	3
@DRUG$ and rifampin should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy ofthe drug.	0
Nevirapine and @DRUG$ should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy ofthe drug.	0
Physicians needing to treatpatients co-infected with tuberculosis andusing a @DRUG$ containing regimen mayuse @DRUG$ instead.	0
aBased on reports of narcotic withdrawal syndrome in patients treated with @DRUG$ and @DRUG$ concurrently, and evidence of decreased plasma concentrations of methadone.	4
aBased on reports of narcotic withdrawal syndrome in patients treated with @DRUG$ and methadone concurrently, and evidence of decreased plasma concentrations of @DRUG$.	0
aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and @DRUG$ concurrently, and evidence of decreased plasma concentrations of @DRUG$.	0
@DRUG$, @DRUG$, lidocaine	0
@DRUG$, disopyramide, @DRUG$	0
Amiodarone, @DRUG$, @DRUG$	0
@DRUG$, @DRUG$, ethosuximide	0
@DRUG$, clonazepam, @DRUG$	0
Carbamazepine, @DRUG$, @DRUG$	0
@DRUG$, @DRUG$, verapamil	0
@DRUG$, nifedipine, @DRUG$	0
Diltiazem, @DRUG$, @DRUG$	0
@DRUG$, @DRUG$, sirolimus	0
@DRUG$, tacrolimus, @DRUG$	0
Cyclosporin, @DRUG$, @DRUG$	0
@DRUG$ should be administered with caution to patients who are taking other @DRUG$ or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	3
@DRUG$ should be administered with caution to patients who are taking other psychoactive drugs or @DRUG$, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	3
@DRUG$ should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including @DRUG$, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	3
@DRUG$ should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, @DRUG$ and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	3
@DRUG$ should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and @DRUG$, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	3
Nabilone should be administered with caution to patients who are taking other @DRUG$ or @DRUG$, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	0
Nabilone should be administered with caution to patients who are taking other @DRUG$ or CNS depressants, including @DRUG$, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	0
Nabilone should be administered with caution to patients who are taking other @DRUG$ or CNS depressants, including alcohol, @DRUG$ and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	0
Nabilone should be administered with caution to patients who are taking other @DRUG$ or CNS depressants, including alcohol, barbiturates and @DRUG$, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	0
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or @DRUG$, including @DRUG$, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	0
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or @DRUG$, including alcohol, @DRUG$ and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	0
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or @DRUG$, including alcohol, barbiturates and @DRUG$, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	0
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including @DRUG$, @DRUG$ and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	0
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including @DRUG$, barbiturates and @DRUG$, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	0
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, @DRUG$ and @DRUG$, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).	0
@DRUG$ has been shown to have an additive CNS depressant effect when given with either @DRUG$, secobarbitone sodium, alcohol or codeine.	4
@DRUG$ has been shown to have an additive CNS depressant effect when given with either diazepam, @DRUG$, alcohol or codeine.	4
@DRUG$ has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, @DRUG$ or codeine.	4
@DRUG$ has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or @DRUG$.	4
Nabilone has been shown to have an additive CNS depressant effect when given with either @DRUG$, @DRUG$, alcohol or codeine.	0
Nabilone has been shown to have an additive CNS depressant effect when given with either @DRUG$, secobarbitone sodium, @DRUG$ or codeine.	0
Nabilone has been shown to have an additive CNS depressant effect when given with either @DRUG$, secobarbitone sodium, alcohol or @DRUG$.	0
Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, @DRUG$, @DRUG$ or codeine.	0
Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, @DRUG$, alcohol or @DRUG$.	0
Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, @DRUG$ or @DRUG$.	0
In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, @DRUG$ 7.5 mg (1.5 times the daily dose) once daily was coadministered with @DRUG$ 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days.	0
In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, @DRUG$ 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or @DRUG$ 200 mg every 12 hours for 10 days.	0
In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with @DRUG$ 500 mg every 8 hours or @DRUG$ 200 mg every 12 hours for 10 days.	0
In three separate controlled, parallel group clinical pharmacology studies, @DRUG$ at the clinical dose of 5 mg has been coadministered with @DRUG$ 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	0
In three separate controlled, parallel group clinical pharmacology studies, @DRUG$ at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with @DRUG$ 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	0
In three separate controlled, parallel group clinical pharmacology studies, @DRUG$ at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with @DRUG$ (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	0
In three separate controlled, parallel group clinical pharmacology studies, @DRUG$ at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with @DRUG$ 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	0
In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with @DRUG$ 500 mg followed by 250 mg once daily for 4 days (n=18) or with @DRUG$ 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	0
In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with @DRUG$ 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with @DRUG$ (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	0
In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with @DRUG$ 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with @DRUG$ 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	0
In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with @DRUG$ 20 mg once daily for 7 days after a 23 day pretreatment period with @DRUG$ (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	0
In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with @DRUG$ 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with @DRUG$ 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	0
In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with @DRUG$ (n=18) or with @DRUG$ 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.	0
Although increased plasma concentrations (C max and AUC 0-24 hrs) of @DRUG$ and @DRUG$ were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.	0
Although increased plasma concentrations (C max and AUC 0-24 hrs) of @DRUG$ and 3-hydroxydesloratadine were observed , there were no clinically relevant changes in the safety profile of @DRUG$, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.	0
Although increased plasma concentrations (C max and AUC 0-24 hrs) of desloratadine and @DRUG$ were observed , there were no clinically relevant changes in the safety profile of @DRUG$, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.	0
Table 1 Changes in @DRUG$ and @DRUG$ Pharmacokinetics in Healthy Male and Female Volunteers	0
@DRUG$ @DRUG$	0
The potential for increased sedation when @DRUG$ is given with other @DRUG$ should be appreciated.	4
The administration of @DRUG$ concomitantly with known microsomal enzyme inducer (@DRUG$ or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.	1
The administration of @DRUG$ concomitantly with known microsomal enzyme inducer (phenobarbital or @DRUG$) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.	1
The administration of guanfacine concomitantly with known microsomal enzyme inducer (@DRUG$ or @DRUG$) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.	0
@DRUG$ decrease the hypotensive effect of @DRUG$.	4
@DRUG$ (@DRUG$,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.	0
@DRUG$ (nadolol,porpranolol,@DRUG$) may exacerbate rebound hypertension when guanfacine is withdrawn.	0
@DRUG$ (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when @DRUG$ is withdrawn.	4
Noncardioselective beta-blockers (@DRUG$,porpranolol,@DRUG$) may exacerbate rebound hypertension when guanfacine is withdrawn.	0
Noncardioselective beta-blockers (@DRUG$,porpranolol,timolol) may exacerbate rebound hypertension when @DRUG$ is withdrawn.	4
Noncardioselective beta-blockers (nadolol,porpranolol,@DRUG$) may exacerbate rebound hypertension when @DRUG$ is withdrawn.	4
The gradual withdrawal of @DRUG$ or a @DRUG$ could be substituted.	0
@DRUG$: Ten patients who were stabilized on oral @DRUG$ were given guanfacine, 1-2 mg/day, for 4 weeks.	0
@DRUG$: Ten patients who were stabilized on oral anticoagulants were given @DRUG$, 1-2 mg/day, for 4 weeks.	0
Anticoagulants: Ten patients who were stabilized on oral @DRUG$ were given @DRUG$, 1-2 mg/day, for 4 weeks.	0
In several well-controlled studies, @DRUG$ was administered together with @DRUG$ with no drug interactions reported.	0
The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: @DRUG$ (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), @DRUG$ and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and @DRUG$ (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), @DRUG$ (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral @DRUG$ (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), @DRUG$ (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), @DRUG$ (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), @DRUG$ (24), oral contraceptives (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), @DRUG$ (13), insulin (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), @DRUG$ (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral @DRUG$ (18), bronchodilators (13), insulin (10), and @DRUG$ (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), @DRUG$ (10), and beta blockers (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), @DRUG$ (13), insulin (10), and @DRUG$ (10).	0
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), @DRUG$ (10), and @DRUG$ (10).	0
@DRUG$ - Taking @DRUG$ and a phenothiazine together may increase the risk of convulsions (seizures).	0
@DRUG$ - Taking piperazine and a @DRUG$ together may increase the risk of convulsions (seizures).	0
Phenothiazines - Taking @DRUG$ and a @DRUG$ together may increase the risk of convulsions (seizures).	4
@DRUG$ (e.g., @DRUG$) - Taking piperazine and pyrantel together may decrease the effects of piperazine.	0
@DRUG$ (e.g., Antiminth) - Taking @DRUG$ and pyrantel together may decrease the effects of piperazine.	0
@DRUG$ (e.g., Antiminth) - Taking piperazine and @DRUG$ together may decrease the effects of piperazine.	0
@DRUG$ (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of @DRUG$.	0
Pyrantel (e.g., @DRUG$) - Taking @DRUG$ and pyrantel together may decrease the effects of piperazine.	0
Pyrantel (e.g., @DRUG$) - Taking piperazine and @DRUG$ together may decrease the effects of piperazine.	0
Pyrantel (e.g., @DRUG$) - Taking piperazine and pyrantel together may decrease the effects of @DRUG$.	0
Pyrantel (e.g., Antiminth) - Taking @DRUG$ and @DRUG$ together may decrease the effects of piperazine.	4
Pyrantel (e.g., Antiminth) - Taking @DRUG$ and pyrantel together may decrease the effects of @DRUG$.	0
Pyrantel (e.g., Antiminth) - Taking piperazine and @DRUG$ together may decrease the effects of @DRUG$.	0
The effects of @DRUG$ and @DRUG$ upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.  	0
The effects of @DRUG$ and L-CCG-1 upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.  	0
The effects of @DRUG$ and L-CCG-1 upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.  	0
The effects of DCG-IV and @DRUG$ upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.  	0
The effects of DCG-IV and @DRUG$ upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.  	0
The effects of DCG-IV and L-CCG-1 upon @DRUG$ (@DRUG$)-induced locomotion and behavioral changes in mice.  	0
injection of @DRUG$ (@DRUG$) were observed by measuring locomotor activity and stereotyped behavior. 	0
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and @DRUG$, on the above behavioral changes induced by PCP were found. 	0
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and L-CCG-1, on the above behavioral changes induced by @DRUG$ were found. 	0
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and @DRUG$, on the above behavioral changes induced by @DRUG$ were found. 	0
The effects of @DRUG$ were very strong and completely depressed the @DRUG$-induced hyperlocomotion. 	4
In order to examine some molecular mechanisms of @DRUG$-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with @DRUG$, DCG-IV, and L-CCG-1 was carried out.	0
In order to examine some molecular mechanisms of @DRUG$-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, @DRUG$, and L-CCG-1 was carried out.	0
In order to examine some molecular mechanisms of @DRUG$-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and @DRUG$ was carried out.	0
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with @DRUG$, @DRUG$, and L-CCG-1 was carried out.	0
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with @DRUG$, DCG-IV, and @DRUG$ was carried out.	0
In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, @DRUG$, and @DRUG$ was carried out.	0
@DRUG$ may accentuate the electrolyte loss associated with @DRUG$ therapy.	4
@DRUG$ and @DRUG$: a drug interaction.  	2
The drug interaction between @DRUG$ and @DRUG$ is not well known. 	2
@DRUG$ has been reported to increase the @DRUG$ requirements in human subjects ingesting these agents simultaneously. 	1
The concomitant administration of @DRUG$ and @DRUG$ resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. 	1
The concomitant administration of @DRUG$ and warfarin resulted in the need for an unusually high maintenance dose of @DRUG$ (20 mg per day) in order to produce a therapeutic effect. 	0
The concomitant administration of rifampin and @DRUG$ resulted in the need for an unusually high maintenance dose of @DRUG$ (20 mg per day) in order to produce a therapeutic effect. 	0
Withdrawal of @DRUG$ decreased the @DRUG$ requirement by 50%. 	1
This effect may be mediated by the ability of @DRUG$ to induce microsomal enzymes and, thus, the catabolism of @DRUG$. 	1
The effect of @DRUG$ on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 	4
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal. 	0
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal. 	0
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal. 	0
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal. 	0
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after @DRUG$ withdrawal. 	0
Treatment with @DRUG$ can directly interfere with blood glucose levels or may interact with @DRUG$. 	2
@DRUG$ (5 mg/kg), @DRUG$ (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	0
@DRUG$ (5 mg/kg), moclobemide (30 mg/kg), @DRUG$ (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	0
@DRUG$ (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), @DRUG$ (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	0
@DRUG$ (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered. 	0
Imipramine (5 mg/kg), @DRUG$ (30 mg/kg), @DRUG$ (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	0
Imipramine (5 mg/kg), @DRUG$ (30 mg/kg), clonazepam (0.25 mg/kg), @DRUG$ (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	0
Imipramine (5 mg/kg), @DRUG$ (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered. 	0
Imipramine (5 mg/kg), moclobemide (30 mg/kg), @DRUG$ (0.25 mg/kg), @DRUG$ (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 	0
Imipramine (5 mg/kg), moclobemide (30 mg/kg), @DRUG$ (0.25 mg/kg), fluoxetine (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered. 	0
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), @DRUG$ (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered. 	0
An oral @DRUG$ overload of 1 ml of a 50% @DRUG$ solution was given to rats and blood glucose was determined after 30, 60 and 90 min. 	0
@DRUG$ and @DRUG$ did not change fasting or overload glycemia. 	0
@DRUG$ and @DRUG$ increased blood glucose at different times after the glucose overload. 	0
@DRUG$ and moclobemide increased blood @DRUG$ at different times after the glucose overload. 	0
Fluoxetine and @DRUG$ increased blood @DRUG$ at different times after the glucose overload. 	0
@DRUG$ neutralized the increase of glycemia induced by oral @DRUG$ overload. 	0
In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of @DRUG$ tolerance 30 min after @DRUG$ overload. 	0
Again, @DRUG$ neutralized the increase in glycemia after @DRUG$ overload both in diabetic and non-diabetic rats. 	0
May interact @DRUG$ (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	0
May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	0
May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	0
May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	0
May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	0
May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	0
May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	0
May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	0
May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	0
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	0
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	0
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	0
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), @DRUG$ (increased effect of corticosteroids).	0
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of @DRUG$).	0
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of @DRUG$).	0
Although @DRUG$ used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with @DRUG$ and epinephrine may occur.	0
Although @DRUG$ used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and @DRUG$ may occur.	0
Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with @DRUG$ and @DRUG$ may occur.	4
Close observation of the patient is recommended when a @DRUG$ is administered to patients receiving catecholamine-depleting drugs such as @DRUG$, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.	3
Patients receiving @DRUG$ along with either oral or intravenous @DRUG$ should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.	3
The concomitant use of @DRUG$ with @DRUG$ and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.	4
The concomitant use of @DRUG$ with digitalis and @DRUG$s may have additive effects on prolonging atrioventricular conduction time.	4
The concomitant use of beta-adrenergic blocking agents with @DRUG$ and @DRUG$s may have additive effects on prolonging atrioventricular conduction time.	0
@DRUG$ and @DRUG$ may have additive hypotensite effects due to the inhibition of each other s metabolism.	1
Catecholamine-depleting drugs, e.g., @DRUG$, may have an additive effect when given with @DRUG$.	4
Patients treated concurrently with @DRUG$ (@DRUG$) and a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.	0
A study of interaction between @DRUG$ and @DRUG$ showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.	0
A study of interaction between @DRUG$ and warfarin showed that concomitant administration of @DRUG$ and warfarin does not alter warfarin plasma levels.	0
A study of interaction between @DRUG$ and warfarin showed that concomitant administration of BREVIBLOC and @DRUG$ does not alter warfarin plasma levels.	0
A study of interaction between @DRUG$ and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter @DRUG$ plasma levels.	0
A study of interaction between BREVIBLOC and @DRUG$ showed that concomitant administration of @DRUG$ and warfarin does not alter warfarin plasma levels.	0
A study of interaction between BREVIBLOC and @DRUG$ showed that concomitant administration of BREVIBLOC and @DRUG$ does not alter warfarin plasma levels.	0
A study of interaction between BREVIBLOC and @DRUG$ showed that concomitant administration of BREVIBLOC and warfarin does not alter @DRUG$ plasma levels.	0
A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of @DRUG$ and @DRUG$ does not alter warfarin plasma levels.	0
A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of @DRUG$ and warfarin does not alter @DRUG$ plasma levels.	0
A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and @DRUG$ does not alter @DRUG$ plasma levels.	0
@DRUG$ concentrations were equivocally higher when given with @DRUG$, but this is not likely to be clinically important.	1
When @DRUG$ and @DRUG$ were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.	1
When @DRUG$ and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in @DRUG$ blood levels at some time points.	0
When digoxin and @DRUG$ were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in @DRUG$ blood levels at some time points.	0
@DRUG$ did not affect @DRUG$ pharmacokinetics.	0
When intravenous @DRUG$ and @DRUG$ were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.	0
When intravenous @DRUG$ and BREVIBLOC were concomitantly administered in normal subjects, no effect on @DRUG$ blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.	0
When intravenous @DRUG$ and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but @DRUG$ steady-state blood levels were increased by 46% in the presence of morphine.	0
When intravenous @DRUG$ and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of @DRUG$.	0
When intravenous morphine and @DRUG$ were concomitantly administered in normal subjects, no effect on @DRUG$ blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.	0
When intravenous morphine and @DRUG$ were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but @DRUG$ steady-state blood levels were increased by 46% in the presence of morphine.	0
When intravenous morphine and @DRUG$ were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of @DRUG$.	0
When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on @DRUG$ blood levels was seen, but @DRUG$ steady-state blood levels were increased by 46% in the presence of morphine.	0
When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on @DRUG$ blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of @DRUG$.	0
When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but @DRUG$ steady-state blood levels were increased by 46% in the presence of @DRUG$.	1
The effect of @DRUG$ on the duration of @DRUG$-induced neuromuscular blockade was studied in patients undergoing surgery.	0
The onset of neuromuscular blockade by @DRUG$ was unaffected by @DRUG$, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.	4
Although the interactions observed in these studies do not appear to be of major clinical importance, @DRUG$ should be titrated with caution in patients being treated concurrently with @DRUG$, morphine, succinylcholine or warfarin.	3
Although the interactions observed in these studies do not appear to be of major clinical importance, @DRUG$ should be titrated with caution in patients being treated concurrently with digoxin, @DRUG$, succinylcholine or warfarin.	3
Although the interactions observed in these studies do not appear to be of major clinical importance, @DRUG$ should be titrated with caution in patients being treated concurrently with digoxin, morphine, @DRUG$ or warfarin.	3
Although the interactions observed in these studies do not appear to be of major clinical importance, @DRUG$ should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or @DRUG$.	3
Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with @DRUG$, @DRUG$, succinylcholine or warfarin.	0
Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with @DRUG$, morphine, @DRUG$ or warfarin.	0
Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with @DRUG$, morphine, succinylcholine or @DRUG$.	0
Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, @DRUG$, @DRUG$ or warfarin.	0
Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, @DRUG$, succinylcholine or @DRUG$.	0
Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, @DRUG$ or @DRUG$.	0
Caution should be exercised when considering the use of @DRUG$ and @DRUG$ in patients with depressed myocardial function.	3
Additionally, @DRUG$ should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as @DRUG$, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.	3
Additionally, @DRUG$ should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, @DRUG$, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.	3
Additionally, @DRUG$ should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and @DRUG$ because of the danger of blocking cardiac contractility when systemic vascular resistance is high.	3
Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as @DRUG$, @DRUG$, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.	0
Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as @DRUG$, epinephrine, and @DRUG$ because of the danger of blocking cardiac contractility when systemic vascular resistance is high.	0
Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, @DRUG$, and @DRUG$ because of the danger of blocking cardiac contractility when systemic vascular resistance is high.	0
The potential for clinically significant drug-drug interactions posed by @DRUG$ and @DRUG$ appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.	0
The potential for clinically significant drug-drug interactions posed by @DRUG$ and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because @DRUG$ is eliminated by multiple routes.	0
The potential for clinically significant drug-drug interactions posed by dolasetron and @DRUG$ appears to be low for drugs commonly used in chemotherapy or surgery, because @DRUG$ is eliminated by multiple routes.	0
Blood levels of @DRUG$ increased 24% when @DRUG$ was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.	0
Blood levels of @DRUG$ increased 24% when dolasetron was coadministered with @DRUG$ (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.	0
Blood levels of @DRUG$ increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of @DRUG$ (potent inducer of cytochrome P-450) for 7 days.	0
Blood levels of hydrodolasetron increased 24% when @DRUG$ was coadministered with @DRUG$ (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.	1
Blood levels of hydrodolasetron increased 24% when @DRUG$ was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of @DRUG$ (potent inducer of cytochrome P-450) for 7 days.	1
Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with @DRUG$ (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of @DRUG$ (potent inducer of cytochrome P-450) for 7 days.	0
In patients taking @DRUG$, @DRUG$, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking @DRUG$, nifedipine, @DRUG$, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking @DRUG$, nifedipine, diltiazem, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	0
In patients taking furosemide, @DRUG$, @DRUG$, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, @DRUG$, diltiazem, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	0
In patients taking furosemide, nifedipine, @DRUG$, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	0
In patients taking furosemide, nifedipine, diltiazem, @DRUG$, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, nifedipine, diltiazem, @DRUG$, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, nifedipine, diltiazem, @DRUG$, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, nifedipine, diltiazem, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	0
In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, @DRUG$, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, @DRUG$, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	0
In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, @DRUG$, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	0
In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	0
In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	0
Clearance of @DRUG$ decreased by about 27% when @DRUG$ was administered intravenously concomitantly with atenolol.	0
Clearance of @DRUG$ decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with @DRUG$.	0
Clearance of hydrodolasetron decreased by about 27% when @DRUG$ was administered intravenously concomitantly with @DRUG$.	1
@DRUG$ did not inhibit the antitumor activity of four @DRUG$ (cisplatin, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.	0
@DRUG$ did not inhibit the antitumor activity of four chemotherapeutic agents (@DRUG$, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.	0
@DRUG$ did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, @DRUG$, doxorubicin, cyclophosphamide) in four murine models.	0
@DRUG$ did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, @DRUG$, cyclophosphamide) in four murine models.	0
@DRUG$ did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, doxorubicin, @DRUG$) in four murine models.	0
Dolasetron mesylate did not inhibit the antitumor activity of four @DRUG$ (@DRUG$, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.	0
Dolasetron mesylate did not inhibit the antitumor activity of four @DRUG$ (cisplatin, @DRUG$, doxorubicin, cyclophosphamide) in four murine models.	0
Dolasetron mesylate did not inhibit the antitumor activity of four @DRUG$ (cisplatin, 5-fluorouracil, @DRUG$, cyclophosphamide) in four murine models.	0
Dolasetron mesylate did not inhibit the antitumor activity of four @DRUG$ (cisplatin, 5-fluorouracil, doxorubicin, @DRUG$) in four murine models.	0
Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (@DRUG$, @DRUG$, doxorubicin, cyclophosphamide) in four murine models.	0
Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (@DRUG$, 5-fluorouracil, @DRUG$, cyclophosphamide) in four murine models.	0
Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (@DRUG$, 5-fluorouracil, doxorubicin, @DRUG$) in four murine models.	0
Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, @DRUG$, @DRUG$, cyclophosphamide) in four murine models.	0
Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, @DRUG$, doxorubicin, @DRUG$) in four murine models.	0
Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, @DRUG$, @DRUG$) in four murine models.	0
Renal function should be monitored carefully if high doses of @DRUG$ are to be administered with @DRUG$ because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.	3
Renal function should be monitored carefully if high doses of @DRUG$ are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of @DRUG$.	0
Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with @DRUG$ because of the increased potential of nephrotoxicity and ototoxicity of @DRUG$.	0
Nephrotoxicity has been reported following concomitant administration of other @DRUG$ with potent @DRUG$ such as furosemide.	4
Nephrotoxicity has been reported following concomitant administration of other @DRUG$ with potent diuretics such as @DRUG$.	4
Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent @DRUG$ such as @DRUG$.	0
Potential for Other Drugs to Affect @DRUG$: Both CYP1A2 and CYP2D6 are responsible for @DRUG$ metabolism.	0
Inhibitors of CYP1A2: Concomitant use of @DRUG$ with @DRUG$, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.	1
Inhibitors of CYP1A2: Concomitant use of @DRUG$ with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of @DRUG$.	0
Inhibitors of CYP1A2: Concomitant use of duloxetine with @DRUG$, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of @DRUG$.	0
Inhibitors of CYP2D6: Because CYP2D6 is involved in @DRUG$ metabolism, concomitant use of @DRUG$ with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.	0
Inhibitors of CYP2D6: Because CYP2D6 is involved in @DRUG$ metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of @DRUG$.	0
Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of @DRUG$ with potent inhibitors of CYP2D6 may result in higher concentrations of @DRUG$.	0
@DRUG$ (20 mg QD) increased the concentration of @DRUG$ (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.	1
@DRUG$ (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of @DRUG$.	0
Paroxetine (20 mg QD) increased the concentration of @DRUG$ (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of @DRUG$.	0
Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., @DRUG$, @DRUG$).	0
Potential for @DRUG$ to Affect Other Drugs: Drugs Metabolized by CYP1A2: In vitro drug interaction studies demonstrate that @DRUG$ does not induce CYP1A2 activity, and it is unlikely to have a clinically significant effect on the metabolism of CYP1A2 substrates.	0
When @DRUG$ was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of @DRUG$, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.	1
When @DRUG$ was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of @DRUG$ increased 3-fold.	0
When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of @DRUG$, a CYP2D6 substrate, the AUC of @DRUG$ increased 3-fold.	0
Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	3
Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	3
Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	3
Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	3
Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	3
Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	3
Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	3
Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	3
Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	3
Therefore, co-administration of @DRUG$ with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	3
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain @DRUG$ (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (@DRUG$ [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [@DRUG$], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as @DRUG$, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, @DRUG$, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and @DRUG$), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), @DRUG$ and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., @DRUG$, flecainide), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and @DRUG$ (e.g., propafenone, @DRUG$), should be approached with caution.	0
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., @DRUG$, @DRUG$), should be approached with caution.	0
Plasma @DRUG$ concentrations may need to be monitored and the dose of the @DRUG$ may need to be reduced if a TCA is co-administered with Duloxetine.	0
Plasma @DRUG$ concentrations may need to be monitored and the dose of the TCA may need to be reduced if a @DRUG$ is co-administered with Duloxetine.	0
Plasma @DRUG$ concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with @DRUG$.	0
Plasma TCA concentrations may need to be monitored and the dose of the @DRUG$ may need to be reduced if a @DRUG$ is co-administered with Duloxetine.	0
Plasma TCA concentrations may need to be monitored and the dose of the @DRUG$ may need to be reduced if a TCA is co-administered with @DRUG$.	0
Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a @DRUG$ is co-administered with @DRUG$.	3
Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of @DRUG$, @DRUG$ and thioridazine should not be co-administered.	0
Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of @DRUG$, Duloxetine and @DRUG$ should not be co-administered.	0
Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, @DRUG$ and @DRUG$ should not be co-administered.	3
@DRUG$ May Have a Clinically Important Interaction with the Following Other Drugs: @DRUG$: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.	0
@DRUG$ May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When @DRUG$ and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.	0
@DRUG$ May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and @DRUG$ were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.	0
@DRUG$ May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, @DRUG$ did not increase the impairment of mental and motor skills caused by alcohol.	0
@DRUG$ May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by @DRUG$.	0
Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: @DRUG$: When @DRUG$ and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.	0
Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: @DRUG$: When Duloxetine and @DRUG$ were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.	0
Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: @DRUG$: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, @DRUG$ did not increase the impairment of mental and motor skills caused by alcohol.	0
Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: @DRUG$: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by @DRUG$.	0
Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When @DRUG$ and @DRUG$ were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.	0
Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When @DRUG$ and ethanol were administered several hours apart so that peak concentrations of each would coincide, @DRUG$ did not increase the impairment of mental and motor skills caused by alcohol.	0
Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When @DRUG$ and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by @DRUG$.	0
Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and @DRUG$ were administered several hours apart so that peak concentrations of each would coincide, @DRUG$ did not increase the impairment of mental and motor skills caused by alcohol.	0
Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and @DRUG$ were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by @DRUG$.	0
Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, @DRUG$ did not increase the impairment of mental and motor skills caused by @DRUG$.	0
In the @DRUG$ clinical trials database, three @DRUG$-treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction.	0
However, co-administration of @DRUG$ with @DRUG$- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of @DRUG$ with aluminum- and @DRUG$-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of @DRUG$ with aluminum- and magnesium-containing @DRUG$ (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of @DRUG$ with aluminum- and magnesium-containing antacids (51 mEq) or @DRUG$ with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of @DRUG$ with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with @DRUG$, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of @DRUG$ with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of @DRUG$ absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with @DRUG$- and @DRUG$-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with @DRUG$- and magnesium-containing @DRUG$ (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with @DRUG$- and magnesium-containing antacids (51 mEq) or @DRUG$ with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with @DRUG$- and magnesium-containing antacids (51 mEq) or Duloxetine with @DRUG$, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with @DRUG$- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of @DRUG$ absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with aluminum- and @DRUG$-containing @DRUG$ (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with aluminum- and @DRUG$-containing antacids (51 mEq) or @DRUG$ with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with aluminum- and @DRUG$-containing antacids (51 mEq) or Duloxetine with @DRUG$, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with aluminum- and @DRUG$-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of @DRUG$ absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with aluminum- and magnesium-containing @DRUG$ (51 mEq) or @DRUG$ with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with aluminum- and magnesium-containing @DRUG$ (51 mEq) or Duloxetine with @DRUG$, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with aluminum- and magnesium-containing @DRUG$ (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of @DRUG$ absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or @DRUG$ with @DRUG$, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or @DRUG$ with famotidine, had no significant effect on the rate or extent of @DRUG$ absorption after administration of a 40-mg oral dose.	0
However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with @DRUG$, had no significant effect on the rate or extent of @DRUG$ absorption after administration of a 40-mg oral dose.	0
It is unknown whether the concomitant administration of @DRUG$ affects @DRUG$ absorption.	0
The rate of metabolism and the leukopenic activity of @DRUG$ reportedly are increased by chronic administration of high doses of @DRUG$.	1
The physician should be alert for possible combined drug actions, desirable or undesirable, involving @DRUG$ even though @DRUG$ has been used successfully concurrently with other drugs, including other cytotoxic drugs.	0
@DRUG$ treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of @DRUG$.	4
Concomitant treatment with @DRUG$ (eg, rt-PA or @DRUG$) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation	0
Concomitant treatment with @DRUG$ (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of @DRUG$ on aPTT prolongation	0
Concomitant treatment with thrombolytics (eg, rt-PA or @DRUG$) may: - increase the risk of bleeding complications - considerably enhance the effect of @DRUG$ on aPTT prolongation	0
Concomitant treatment with @DRUG$ (@DRUG$) and drugs that affect platelet function may also increase the risk of bleeding.	0
However, it was observed that the pharmacokinetics of @DRUG$  was unaltered by concomitant @DRUG$ in rheumatoid arthritis patients.	0
In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$  and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).	4
In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$  alone (0%).	0
In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$  alone (0%).	0
Two percent of patients treated concurrently with @DRUG$  and @DRUG$ developed neutropenia (ANC   1 x 109/L).	4
Patients in a clinical study who were on established therapy with @DRUG$, to which @DRUG$ was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.	4
Patients in a clinical study who were on established therapy with @DRUG$, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or sulfasalazine alone.	0
Patients in a clinical study who were on established therapy with @DRUG$, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or @DRUG$ alone.	0
Patients in a clinical study who were on established therapy with sulfasalazine, to which @DRUG$ was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or sulfasalazine alone.	0
Patients in a clinical study who were on established therapy with sulfasalazine, to which @DRUG$ was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or @DRUG$ alone.	0
Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or @DRUG$ alone.	0
When @DRUG$ and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.	4
When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because pralidoxime may potentiate the effect of atropine.	0
When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because @DRUG$ may potentiate the effect of atropine.	0
When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of @DRUG$.	0
When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because pralidoxime may potentiate the effect of atropine.	0
When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because @DRUG$ may potentiate the effect of atropine.	0
When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of @DRUG$.	0
When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because @DRUG$ may potentiate the effect of atropine.	0
When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because pralidoxime may potentiate the effect of @DRUG$.	0
When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because @DRUG$ may potentiate the effect of @DRUG$.	4
The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of @DRUG$ and @DRUG$.	3
Since @DRUG$ are potentiated by the @DRUG$, they should be used cautiously in the treatment of convulsions.	3
@DRUG$ (@DRUG$) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.  	0
@DRUG$ (18-MC) and @DRUG$: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.  	0
18-Methoxycoronaridine (@DRUG$) and @DRUG$: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.  	0
Like @DRUG$ (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 	0
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats; 	0
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats; 	0
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats; 	0
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats; 	0
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats; 	0
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats; 	0
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats; 	0
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats; 	0
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and @DRUG$ and the oral self-administration of ethanol and nicotine in rats; 	0
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of @DRUG$ and nicotine in rats; 	0
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and @DRUG$ in rats; 	0
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of @DRUG$ and nicotine in rats; 	0
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and @DRUG$ in rats; 	0
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and @DRUG$ in rats; 	0
unlike @DRUG$, @DRUG$ does not affect responding for a nondrug reinforcer (water). 	0
Both @DRUG$ and @DRUG$ ameliorate opioid withdrawal signs. 	0
Both @DRUG$ and 18-MC ameliorate @DRUG$ withdrawal signs. 	0
Both ibogaine and @DRUG$ ameliorate @DRUG$ withdrawal signs. 	0
Both @DRUG$ and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. 	0
Both @DRUG$ and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens. 	0
Both ibogaine and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens. 	0
Both @DRUG$ and @DRUG$ block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; 	0
Both @DRUG$ and 18-MC block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens; 	4
Both @DRUG$ and 18-MC block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens; 	4
Both ibogaine and @DRUG$ block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens; 	4
Both ibogaine and @DRUG$ block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens; 	4
Both ibogaine and 18-MC block @DRUG$-induced and @DRUG$-induced dopamine release in the nucleus accumbens; 	0
only @DRUG$ enhances @DRUG$-induced increases in accumbal dopamine. 	4
Both @DRUG$ and @DRUG$ enhance the locomotor and/or stereotypic effects of stimulants. 	0
@DRUG$ attenuates, but @DRUG$ potentiates, the acute locomotor effects of morphine; 	0
@DRUG$ attenuates, but 18-MC potentiates, the acute locomotor effects of @DRUG$; 	4
Ibogaine attenuates, but @DRUG$ potentiates, the acute locomotor effects of @DRUG$; 	4
both compounds attenuate @DRUG$-induced locomotion in @DRUG$-experienced rats. 	0
@DRUG$, but not @DRUG$, decreases heart rate at high doses. 	0
While @DRUG$ and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	0
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	0
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	0
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	0
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	0
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 	0
Both @DRUG$ and @DRUG$ are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 	0
Both @DRUG$ and ibogaine are sequestered in fat and, like @DRUG$, 18-MC probably has an active metabolite. 	0
Both @DRUG$ and ibogaine are sequestered in fat and, like ibogaine, @DRUG$ probably has an active metabolite. 	0
Both 18-MC and @DRUG$ are sequestered in fat and, like @DRUG$, 18-MC probably has an active metabolite. 	0
Both 18-MC and @DRUG$ are sequestered in fat and, like ibogaine, @DRUG$ probably has an active metabolite. 	0
Both 18-MC and ibogaine are sequestered in fat and, like @DRUG$, @DRUG$ probably has an active metabolite. 	0
The data suggest that @DRUG$ has a narrower spectrum of actions and will have a substantially greater therapeutic index than @DRUG$.	0
Effect of @DRUG$ and @DRUG$ on the antinociceptive effect of morphine, metamizol and indomethacin in mice.	0
Effect of @DRUG$ and midazolam on the antinociceptive effect of @DRUG$, metamizol and indomethacin in mice.	0
Effect of @DRUG$ and midazolam on the antinociceptive effect of morphine, @DRUG$ and indomethacin in mice.	0
Effect of @DRUG$ and midazolam on the antinociceptive effect of morphine, metamizol and @DRUG$ in mice.	0
Effect of diazepam and @DRUG$ on the antinociceptive effect of @DRUG$, metamizol and indomethacin in mice.	0
Effect of diazepam and @DRUG$ on the antinociceptive effect of morphine, @DRUG$ and indomethacin in mice.	0
Effect of diazepam and @DRUG$ on the antinociceptive effect of morphine, metamizol and @DRUG$ in mice.	0
Effect of diazepam and midazolam on the antinociceptive effect of @DRUG$, @DRUG$ and indomethacin in mice.	0
Effect of diazepam and midazolam on the antinociceptive effect of @DRUG$, metamizol and @DRUG$ in mice.	0
Effect of diazepam and midazolam on the antinociceptive effect of morphine, @DRUG$ and @DRUG$ in mice.	0
The influence of @DRUG$ and @DRUG$ on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	0
The influence of @DRUG$ and diazepam on antinociceptive effect of @DRUG$ (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	0
The influence of @DRUG$ and diazepam on antinociceptive effect of morphine (10 mg/kg), @DRUG$ (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	0
The influence of @DRUG$ and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and @DRUG$ (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	0
The influence of midazolam and @DRUG$ on antinociceptive effect of @DRUG$ (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	0
The influence of midazolam and @DRUG$ on antinociceptive effect of morphine (10 mg/kg), @DRUG$ (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	0
The influence of midazolam and @DRUG$ on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and @DRUG$ (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	0
The influence of midazolam and diazepam on antinociceptive effect of @DRUG$ (10 mg/kg), @DRUG$ (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	0
The influence of midazolam and diazepam on antinociceptive effect of @DRUG$ (10 mg/kg), metamizol (500 mg/kg) and @DRUG$ (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	0
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), @DRUG$ (500 mg/kg) and @DRUG$ (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 	0
@DRUG$ were administered to mice 30 min before applying the @DRUG$. 	0
@DRUG$ at doses of 0.25 mg/kg and 2.5 mg/kg injected with @DRUG$ was found to decrease the antinociceptive effect of morphine. 	4
@DRUG$ at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of @DRUG$. 	0
Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with @DRUG$ was found to decrease the antinociceptive effect of @DRUG$. 	0
Similarly, @DRUG$ decreased the antinociceptive effect of @DRUG$ (only in the tail-flick test) and indomethacin. 	4
Similarly, @DRUG$ decreased the antinociceptive effect of metamizol (only in the tail-flick test) and @DRUG$. 	4
Similarly, diazepam decreased the antinociceptive effect of @DRUG$ (only in the tail-flick test) and @DRUG$. 	0
@DRUG$ used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of @DRUG$, metamizol (only in the tail-flick test) and indomethacin.	4
@DRUG$ used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, @DRUG$ (only in the tail-flick test) and indomethacin.	4
@DRUG$ used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and @DRUG$.	4
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of @DRUG$, @DRUG$ (only in the tail-flick test) and indomethacin.	0
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of @DRUG$, metamizol (only in the tail-flick test) and @DRUG$.	0
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, @DRUG$ (only in the tail-flick test) and @DRUG$.	0
A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (TMP/SMX).	0
A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (TMP/SMX).	0
A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (@DRUG$/SMX).	0
A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/@DRUG$).	0
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/@DRUG$ (TMP/SMX).	0
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (@DRUG$/SMX).	0
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (TMP/@DRUG$).	0
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (@DRUG$/SMX).	0
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (TMP/@DRUG$).	0
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (@DRUG$/@DRUG$).	0
During co-administration, systemic levels of @DRUG$ and @DRUG$ were essentially unchanged.	0
Notably, systemic exposure (AUC0-12) of @DRUG$ (@DRUG$) was more than doubled in the presence of TMP/SMX.	0
Notably, systemic exposure (AUC0-12) of @DRUG$ (DHA) was more than doubled in the presence of @DRUG$/SMX.	0
Notably, systemic exposure (AUC0-12) of @DRUG$ (DHA) was more than doubled in the presence of TMP/@DRUG$.	0
Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (@DRUG$) was more than doubled in the presence of @DRUG$/SMX.	0
Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (@DRUG$) was more than doubled in the presence of TMP/@DRUG$.	0
Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of @DRUG$/@DRUG$.	0
Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with @DRUG$/@DRUG$.	0
Certain concomitant medications (such as @DRUG$, @DRUG$, St.	0
John s wort) may increase the formation of @DRUG$, a metabolite of @DRUG$ associated with hemolysis.	0
With oral @DRUG$ treatment, @DRUG$ such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions	4
With oral @DRUG$ treatment, folic acid antagonists such as @DRUG$ have been noted to possibly increase the likelihood of hematologic reactions	4
With oral dapsone treatment, @DRUG$ such as @DRUG$ have been noted to possibly increase the likelihood of hematologic reactions	0
May interact with wthionamide (@DRUG$) and @DRUG$ (Nydrazid).	0
May interact with wthionamide (@DRUG$) and isoniazid (@DRUG$).	0
May interact with wthionamide (Trecator-SC) and @DRUG$ (@DRUG$).	0
Certain @DRUG$, especially @DRUG$, streptomycin and kanamycin, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.	0
Certain @DRUG$, especially neomycin, @DRUG$ and kanamycin, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.	0
Certain @DRUG$, especially neomycin, streptomycin and @DRUG$, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.	0
Certain antibiotics, especially @DRUG$, @DRUG$ and kanamycin, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.	0
Certain antibiotics, especially @DRUG$, streptomycin and @DRUG$, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.	0
Certain antibiotics, especially neomycin, @DRUG$ and @DRUG$, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.	0
These @DRUG$ should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive @DRUG$ dosage.	3
Local and some general @DRUG$, @DRUG$ and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all, in patients with myasthenia gravis;	0
@DRUG$ are a major contributing factor to @DRUG$ toxicity.	4
@DRUG$, @DRUG$, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
@DRUG$, verapamil, @DRUG$, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
@DRUG$, verapamil, amiodarone, @DRUG$, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
@DRUG$, verapamil, amiodarone, propafenone, @DRUG$, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
@DRUG$, verapamil, amiodarone, propafenone, indomethacin, @DRUG$, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
@DRUG$, verapamil, amiodarone, propafenone, indomethacin, itraconazole, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
@DRUG$, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
@DRUG$, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	1
@DRUG$, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	0
Quinidine, @DRUG$, @DRUG$, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, @DRUG$, amiodarone, @DRUG$, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, @DRUG$, amiodarone, propafenone, @DRUG$, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, @DRUG$, amiodarone, propafenone, indomethacin, @DRUG$, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, @DRUG$, amiodarone, propafenone, indomethacin, itraconazole, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, @DRUG$, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, @DRUG$, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	1
Quinidine, @DRUG$, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	0
Quinidine, verapamil, @DRUG$, @DRUG$, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, @DRUG$, propafenone, @DRUG$, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, @DRUG$, propafenone, indomethacin, @DRUG$, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, @DRUG$, propafenone, indomethacin, itraconazole, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, @DRUG$, propafenone, indomethacin, itraconazole, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, @DRUG$, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	1
Quinidine, verapamil, @DRUG$, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	0
Quinidine, verapamil, amiodarone, @DRUG$, @DRUG$, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, amiodarone, @DRUG$, indomethacin, @DRUG$, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, amiodarone, @DRUG$, indomethacin, itraconazole, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, amiodarone, @DRUG$, indomethacin, itraconazole, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, amiodarone, @DRUG$, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	1
Quinidine, verapamil, amiodarone, @DRUG$, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	0
Quinidine, verapamil, amiodarone, propafenone, @DRUG$, @DRUG$, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, amiodarone, propafenone, @DRUG$, itraconazole, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, amiodarone, propafenone, @DRUG$, itraconazole, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, amiodarone, propafenone, @DRUG$, itraconazole, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	1
Quinidine, verapamil, amiodarone, propafenone, @DRUG$, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	0
Quinidine, verapamil, amiodarone, propafenone, indomethacin, @DRUG$, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, amiodarone, propafenone, indomethacin, @DRUG$, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, amiodarone, propafenone, indomethacin, @DRUG$, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	1
Quinidine, verapamil, amiodarone, propafenone, indomethacin, @DRUG$, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	0
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, @DRUG$, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	0
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, @DRUG$, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	1
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, @DRUG$, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	0
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and @DRUG$ raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.	1
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and @DRUG$ raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	0
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum @DRUG$ concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that @DRUG$ intoxication may result.	0
@DRUG$ and @DRUG$ (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	0
@DRUG$ and clarithromycin (and possibly other @DRUG$) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	0
@DRUG$ and clarithromycin (and possibly other macrolide antibiotics) and @DRUG$ may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	0
@DRUG$ and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase @DRUG$ absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	1
@DRUG$ and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate @DRUG$ by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	0
@DRUG$ and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that @DRUG$ intoxication may result.	0
Erythromycin and @DRUG$ (and possibly other @DRUG$) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	0
Erythromycin and @DRUG$ (and possibly other macrolide antibiotics) and @DRUG$ may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	0
Erythromycin and @DRUG$ (and possibly other macrolide antibiotics) and tetracycline may increase @DRUG$ absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	1
Erythromycin and @DRUG$ (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate @DRUG$ by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	0
Erythromycin and @DRUG$ (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that @DRUG$ intoxication may result.	0
Erythromycin and clarithromycin (and possibly other @DRUG$) and @DRUG$ may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	0
Erythromycin and clarithromycin (and possibly other @DRUG$) and tetracycline may increase @DRUG$ absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	1
Erythromycin and clarithromycin (and possibly other @DRUG$) and tetracycline may increase digoxin absorption in patients who inactivate @DRUG$ by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	0
Erythromycin and clarithromycin (and possibly other @DRUG$) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that @DRUG$ intoxication may result.	0
Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and @DRUG$ may increase @DRUG$ absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	1
Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and @DRUG$ may increase digoxin absorption in patients who inactivate @DRUG$ by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	0
Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and @DRUG$ may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that @DRUG$ intoxication may result.	0
Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase @DRUG$ absorption in patients who inactivate @DRUG$ by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.	0
Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase @DRUG$ absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that @DRUG$ intoxication may result.	0
Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate @DRUG$ by bacterial metabolism in the lower intestine, so that @DRUG$ intoxication may result.	0
@DRUG$ and @DRUG$, by decreasing gut motility, may increase digoxin absorption.	0
@DRUG$ and diphenoxylate, by decreasing gut motility, may increase @DRUG$ absorption.	1
Propantheline and @DRUG$, by decreasing gut motility, may increase @DRUG$ absorption.	1
@DRUG$, @DRUG$-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
@DRUG$, kaolin-pectin, @DRUG$, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
@DRUG$, kaolin-pectin, sulfasalazine, @DRUG$, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
@DRUG$, kaolin-pectin, sulfasalazine, neomycin, @DRUG$, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
@DRUG$, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and @DRUG$ may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
@DRUG$, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal @DRUG$ absorption, resulting in unexpectedly low serum concentrations.	1
Antacids, @DRUG$-pectin, @DRUG$, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
Antacids, @DRUG$-pectin, sulfasalazine, @DRUG$, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
Antacids, @DRUG$-pectin, sulfasalazine, neomycin, @DRUG$, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
Antacids, @DRUG$-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and @DRUG$ may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
Antacids, @DRUG$-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal @DRUG$ absorption, resulting in unexpectedly low serum concentrations.	1
Antacids, kaolin-pectin, @DRUG$, @DRUG$, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
Antacids, kaolin-pectin, @DRUG$, neomycin, @DRUG$, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
Antacids, kaolin-pectin, @DRUG$, neomycin, cholestyramine, certain anticancer drugs, and @DRUG$ may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
Antacids, kaolin-pectin, @DRUG$, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal @DRUG$ absorption, resulting in unexpectedly low serum concentrations.	1
Antacids, kaolin-pectin, sulfasalazine, @DRUG$, @DRUG$, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
Antacids, kaolin-pectin, sulfasalazine, @DRUG$, cholestyramine, certain anticancer drugs, and @DRUG$ may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
Antacids, kaolin-pectin, sulfasalazine, @DRUG$, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal @DRUG$ absorption, resulting in unexpectedly low serum concentrations.	1
Antacids, kaolin-pectin, sulfasalazine, neomycin, @DRUG$, certain anticancer drugs, and @DRUG$ may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.	0
Antacids, kaolin-pectin, sulfasalazine, neomycin, @DRUG$, certain anticancer drugs, and metoclopramide may interfere with intestinal @DRUG$ absorption, resulting in unexpectedly low serum concentrations.	1
Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and @DRUG$ may interfere with intestinal @DRUG$ absorption, resulting in unexpectedly low serum concentrations.	1
@DRUG$ may decrease serum @DRUG$ concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.	1
@DRUG$ may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of @DRUG$.	0
Rifampin may decrease serum @DRUG$ concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of @DRUG$.	0
There have been inconsistent reports regarding the effects of other drugs (e.g., @DRUG$, @DRUG$) on serum digoxin concentration.	0
There have been inconsistent reports regarding the effects of other drugs (e.g., @DRUG$, penicillamine) on serum @DRUG$ concentration.	0
There have been inconsistent reports regarding the effects of other drugs (e.g., quinine, @DRUG$) on serum @DRUG$ concentration.	0
@DRUG$ administration to a digitalized, hypothyroid patient may increase the dose requirement of @DRUG$.	3
Concomitant use of @DRUG$ and @DRUG$ increases the risk of cardiac arrhythmias.	4
Although @DRUG$ or @DRUG$ and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.	0
Although @DRUG$ or calcium channel blockers and @DRUG$ may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.	4
Although beta-adrenergic blockers or @DRUG$ and @DRUG$ may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.	4
Furthermore, caution should be exercised when combining @DRUG$ with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of @DRUG$.	0
Concomitant use with other @DRUG$-containing medicines (including @DRUG$) may cause too much calcium in the blood or urine, which may increase the chance of side effects.	0
Concomitant use with other @DRUG$-containing medicines (including antacids) may cause too much @DRUG$ in the blood or urine, which may increase the chance of side effects.	0
Concomitant use with other calcium-containing medicines (including @DRUG$) may cause too much @DRUG$ in the blood or urine, which may increase the chance of side effects.	0
Using @DRUG$ with @DRUG$ (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.	4
Using @DRUG$ with digitalis glycosides (heart medicine) may cause hypercalcemia (too much @DRUG$ in the blood), which could increase the chance of developing an irregular heartbeat.	0
Using calcium acetate with @DRUG$ (heart medicine) may cause hypercalcemia (too much @DRUG$ in the blood), which could increase the chance of developing an irregular heartbeat.	0
Special consideration should be given to the administration of @DRUG$ in patients receiving @DRUG$ or other drugs that could cause or potentiate hypotension.	3
Persons taking most @DRUG$, @DRUG$ and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.	0
Persons taking most @DRUG$, methotrexate and @DRUG$ invalidate folic acid and vitamin B12 diagnostic blood assays.	0
Persons taking most @DRUG$, methotrexate and pyrimethamine invalidate @DRUG$ and vitamin B12 diagnostic blood assays.	0
Persons taking most @DRUG$, methotrexate and pyrimethamine invalidate folic acid and @DRUG$ diagnostic blood assays.	0
Persons taking most antibiotics, @DRUG$ and @DRUG$ invalidate folic acid and vitamin B12 diagnostic blood assays.	0
Persons taking most antibiotics, @DRUG$ and pyrimethamine invalidate @DRUG$ and vitamin B12 diagnostic blood assays.	0
Persons taking most antibiotics, @DRUG$ and pyrimethamine invalidate folic acid and @DRUG$ diagnostic blood assays.	0
Persons taking most antibiotics, methotrexate and @DRUG$ invalidate @DRUG$ and vitamin B12 diagnostic blood assays.	0
Persons taking most antibiotics, methotrexate and @DRUG$ invalidate folic acid and @DRUG$ diagnostic blood assays.	0
Persons taking most antibiotics, methotrexate and pyrimethamine invalidate @DRUG$ and @DRUG$ diagnostic blood assays.	0
@DRUG$ @DRUG$ and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.	0
@DRUG$ para-aminosalicylic acid and heavy @DRUG$ intake for longer than 2 weeks may produce malabsorption of vitamin B12.	0
@DRUG$ para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of @DRUG$.	1
Colchicine @DRUG$ and heavy @DRUG$ intake for longer than 2 weeks may produce malabsorption of vitamin B12.	0
Colchicine @DRUG$ and heavy alcohol intake for longer than 2 weeks may produce malabsorption of @DRUG$.	1
Colchicine para-aminosalicylic acid and heavy @DRUG$ intake for longer than 2 weeks may produce malabsorption of @DRUG$.	1
[The effect of @DRUG$ on the renal excretion of @DRUG$ and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	0
[The effect of @DRUG$ on the renal excretion of verografin and @DRUG$ in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	0
[The effect of @DRUG$ on the renal excretion of verografin and iodamide in dogs];The intravenous injection of c@DRUG$in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	0
[The effect of @DRUG$ on the renal excretion of verografin and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced v@DRUG$and iodamide excretion in chronic canine experiments. 	0
[The effect of @DRUG$ on the renal excretion of verografin and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and i@DRUG$excretion in chronic canine experiments. 	0
[The effect of cimetidine on the renal excretion of @DRUG$ and @DRUG$ in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	0
[The effect of cimetidine on the renal excretion of @DRUG$ and iodamide in dogs];The intravenous injection of c@DRUG$in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	0
[The effect of cimetidine on the renal excretion of @DRUG$ and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced v@DRUG$and iodamide excretion in chronic canine experiments. 	0
[The effect of cimetidine on the renal excretion of @DRUG$ and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and i@DRUG$excretion in chronic canine experiments. 	0
[The effect of cimetidine on the renal excretion of verografin and @DRUG$ in dogs];The intravenous injection of c@DRUG$in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 	0
[The effect of cimetidine on the renal excretion of verografin and @DRUG$ in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced v@DRUG$and iodamide excretion in chronic canine experiments. 	0
[The effect of cimetidine on the renal excretion of verografin and @DRUG$ in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and i@DRUG$excretion in chronic canine experiments. 	0
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs];The intravenous injection of c@DRUG$in a dose of 20 mg/kg enhanced v@DRUG$and iodamide excretion in chronic canine experiments. 	1
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs];The intravenous injection of c@DRUG$in a dose of 20 mg/kg enhanced verografine and i@DRUG$excretion in chronic canine experiments. 	1
[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced v@DRUG$and i@DRUG$excretion in chronic canine experiments. 	0
The higher @DRUG$ and @DRUG$ excretion was due to their increased renal tubular secretion. 	0
In dogs, @DRUG$ unchanged the secretion of @DRUG$, a test agent for anionic transport. 	0
Possible extrarenal mechanisms of action of @DRUG$ on @DRUG$ and iodamide transport were also examined.	0
Possible extrarenal mechanisms of action of @DRUG$ on verografine and @DRUG$ transport were also examined.	0
Possible extrarenal mechanisms of action of cimetidine on @DRUG$ and @DRUG$ transport were also examined.	0
The potential effects of @DRUG$ on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days @DRUG$ showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides.	0
METHODS: Clinical studies, case reports, and commentaries and editorials concerning @DRUG$ published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms @DRUG$, Viagra, and erectile dysfunction. 	0
METHODS: Clinical studies, case reports, and commentaries and editorials concerning @DRUG$ published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, @DRUG$, and erectile dysfunction. 	0
METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms @DRUG$, @DRUG$, and erectile dysfunction. 	0
RESULTS: @DRUG$ has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, @DRUG$ [SSRIs]). 	0
RESULTS: @DRUG$ has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [@DRUG$]). 	0
RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, @DRUG$ [@DRUG$]). 	0
however, patients with moderate to severe cardiovascular disease or those taking @DRUG$ therapy are at increased risk for potentially serious cardiovascular adverse effects with @DRUG$ therapy. 	4
In addition, patients taking drugs that inhibit the cytochrome P450 3A4 isozyme, which metabolizes @DRUG$, may experience increased drug concentrations and possible toxicity from normal doses of @DRUG$. 	0
@DRUG$ may interact with @DRUG$ or other CNS depressants, causing increased sedative effects.	4
@DRUG$ may interact with alcohol or other @DRUG$, causing increased sedative effects.	4
Ethopropazine may interact with @DRUG$ or other @DRUG$, causing increased sedative effects.	0
It may also interact with @DRUG$ or other @DRUG$ or MAOIs, which may intensify the anticholinergic action.	0
It may also interact with @DRUG$ or other anticholinergic drugs or @DRUG$, which may intensify the anticholinergic action.	0
It may also interact with amantadine or other @DRUG$ or @DRUG$, which may intensify the anticholinergic action.	0
@DRUG$ can interact with @DRUG$, increasing the metabolism of chlorpromazine.	1
@DRUG$ can interact with chlorpromazine, increasing the metabolism of @DRUG$.	0
Ethopropazine can interact with @DRUG$, increasing the metabolism of @DRUG$.	0
@DRUG$: Administration of @DRUG$ to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).	0
@DRUG$: Administration of flurbiprofen to volunteers under fasting conditions, or with @DRUG$ suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).	0
@DRUG$: Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum @DRUG$ time profiles in young subjects (n=12).	0
Antacids: Administration of @DRUG$ to volunteers under fasting conditions, or with @DRUG$ suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).	0
Antacids: Administration of @DRUG$ to volunteers under fasting conditions, or with antacid suspension yielded similar serum @DRUG$ time profiles in young subjects (n=12).	0
Antacids: Administration of flurbiprofen to volunteers under fasting conditions, or with @DRUG$ suspension yielded similar serum @DRUG$ time profiles in young subjects (n=12).	0
@DRUG$: @DRUG$ like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.	0
@DRUG$: Flurbiprofen like other @DRUG$, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.	0
@DRUG$: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving @DRUG$, and serious clinical bleeding has been reported.	0
Anticoagulants: @DRUG$ like other @DRUG$, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.	0
Anticoagulants: @DRUG$ like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving @DRUG$, and serious clinical bleeding has been reported.	4
Anticoagulants: Flurbiprofen like other @DRUG$, has been shown to affect bleeding parameters in patients receiving @DRUG$, and serious clinical bleeding has been reported.	4
The physician should be cautious when administering @DRUG$ to patients taking @DRUG$.	3
@DRUG$: Concurrent administration of @DRUG$ and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.	0
@DRUG$: Concurrent administration of aspirin and @DRUG$ resulted in 50% lower serum flurbiprofen concentrations.	0
@DRUG$: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum @DRUG$ concentrations.	0
Aspirin: Concurrent administration of @DRUG$ and @DRUG$ resulted in 50% lower serum flurbiprofen concentrations.	1
Aspirin: Concurrent administration of @DRUG$ and flurbiprofen resulted in 50% lower serum @DRUG$ concentrations.	0
Aspirin: Concurrent administration of aspirin and @DRUG$ resulted in 50% lower serum @DRUG$ concentrations.	0
This effect of @DRUG$ (which also lowers serum concentrations of other @DRUG$ given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16).	0
Concurrent use of @DRUG$ and @DRUG$ is therefore not recommended.	3
@DRUG$: The effect of @DRUG$ on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).	0
@DRUG$: The effect of flurbiprofen on blood pressure response to @DRUG$ and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).	0
@DRUG$: The effect of flurbiprofen on blood pressure response to propranolol and @DRUG$ was evaluated in men with mild uncomplicated hypertension (n = 10).	0
Beta-adrenergic Blocking Agents: The effect of @DRUG$ on blood pressure response to @DRUG$ and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).	0
Beta-adrenergic Blocking Agents: The effect of @DRUG$ on blood pressure response to propranolol and @DRUG$ was evaluated in men with mild uncomplicated hypertension (n = 10).	0
Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to @DRUG$ and @DRUG$ was evaluated in men with mild uncomplicated hypertension (n = 10).	0
@DRUG$ pretreatment attenuated the hypotensive effect of a single dose of @DRUG$ but not atenolol.	4
@DRUG$ pretreatment attenuated the hypotensive effect of a single dose of propranolol but not @DRUG$.	0
Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of @DRUG$ but not @DRUG$.	0
@DRUG$ did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with @DRUG$s hypotensive effect is unknown.	2
Patients taking both @DRUG$ and a @DRUG$ should be monitored to ensure that a satisfactory hypotensive effect is achieved.	3
@DRUG$, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	0
@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	0
@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	0
@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	0
@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	0
@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	0
Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	0
Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	0
Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	0
Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	0
Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	0
Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	0
Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	0
Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	0
Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	0
Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	0
Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	0
Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	0
Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	0
Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	0
Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with @DRUG$.	1
@DRUG$: Studies of concomitant administration of @DRUG$ and digoxin to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.	0
@DRUG$: Studies of concomitant administration of flurbiprofen and @DRUG$ to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.	0
Digoxin: Studies of concomitant administration of @DRUG$ and @DRUG$ to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.	0
@DRUG$: Studies in normal volunteers have shown that @DRUG$ like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.	0
@DRUG$: Studies in normal volunteers have shown that flurbiprofen like other @DRUG$, can interfere with the effects of furosemide.	0
@DRUG$: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of @DRUG$.	0
Diuretics: Studies in normal volunteers have shown that @DRUG$ like other @DRUG$, can interfere with the effects of furosemide.	0
Diuretics: Studies in normal volunteers have shown that @DRUG$ like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of @DRUG$.	4
Diuretics: Studies in normal volunteers have shown that flurbiprofen like other @DRUG$, can interfere with the effects of @DRUG$.	4
Other @DRUG$ that inhibit prostaglandin synthesis have been shown to interfere with @DRUG$ in some studies and with potassium-sparing diuretics.	4
Other @DRUG$ that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with @DRUG$.	4
Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with @DRUG$ in some studies and with @DRUG$.	0
Patients receiving @DRUG$ and @DRUG$ or other diuretics should be observed closely to determine if the desired effect is obtained.	3
Patients receiving @DRUG$ and furosemide or other @DRUG$ should be observed closely to determine if the desired effect is obtained.	3
Patients receiving flurbiprofen and @DRUG$ or other @DRUG$ should be observed closely to determine if the desired effect is obtained.	0
Oral @DRUG$: In one study, @DRUG$ was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).	0
Oral @DRUG$: In one study, flurbiprofen was given to adult diabetics who were already receiving @DRUG$ (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).	0
Oral @DRUG$: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), @DRUG$ (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).	0
Oral @DRUG$: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) @DRUG$ with phenformin (n= 3) or glyburide with phenformin (n=6).	0
Oral @DRUG$: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with @DRUG$ (n= 3) or glyburide with phenformin (n=6).	0
Oral @DRUG$: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or @DRUG$ with phenformin (n=6).	0
Oral @DRUG$: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with @DRUG$ (n=6).	0
Oral Hypoglycemic Agents: In one study, @DRUG$ was given to adult diabetics who were already receiving @DRUG$ (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, @DRUG$ was given to adult diabetics who were already receiving glyburide (n=4), @DRUG$ (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, @DRUG$ was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) @DRUG$ with phenformin (n= 3) or glyburide with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, @DRUG$ was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with @DRUG$ (n= 3) or glyburide with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, @DRUG$ was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or @DRUG$ with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, @DRUG$ was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with @DRUG$ (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving @DRUG$ (n=4), @DRUG$ (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving @DRUG$ (n=4), metformin (n=2) @DRUG$ with phenformin (n= 3) or glyburide with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving @DRUG$ (n=4), metformin (n=2) chlorpropamide with @DRUG$ (n= 3) or glyburide with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving @DRUG$ (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or @DRUG$ with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving @DRUG$ (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with @DRUG$ (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), @DRUG$ (n=2) @DRUG$ with phenformin (n= 3) or glyburide with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), @DRUG$ (n=2) chlorpropamide with @DRUG$ (n= 3) or glyburide with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), @DRUG$ (n=2) chlorpropamide with phenformin (n= 3) or @DRUG$ with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), @DRUG$ (n=2) chlorpropamide with phenformin (n= 3) or glyburide with @DRUG$ (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) @DRUG$ with @DRUG$ (n= 3) or glyburide with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) @DRUG$ with phenformin (n= 3) or @DRUG$ with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) @DRUG$ with phenformin (n= 3) or glyburide with @DRUG$ (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with @DRUG$ (n= 3) or @DRUG$ with phenformin (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with @DRUG$ (n= 3) or glyburide with @DRUG$ (n=6).	0
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or @DRUG$ with @DRUG$ (n=6).	0
Although there was a slight reduction in blood sugar concentrations during concomitant administration of @DRUG$ and @DRUG$, there were no signs or symptoms of hypoglycemia.	4
In vitro mixing of an @DRUG$ with beta-lactamtype @DRUG$ (penicillins or cephalosporins) may result in a significant mutual inactivation.	4
In vitro mixing of an @DRUG$ with beta-lactamtype antibiotics (@DRUG$ or cephalosporins) may result in a significant mutual inactivation.	4
In vitro mixing of an @DRUG$ with beta-lactamtype antibiotics (penicillins or @DRUG$) may result in a significant mutual inactivation.	4
In vitro mixing of an aminoglycoside with beta-lactamtype @DRUG$ (@DRUG$ or cephalosporins) may result in a significant mutual inactivation.	0
In vitro mixing of an aminoglycoside with beta-lactamtype @DRUG$ (penicillins or @DRUG$) may result in a significant mutual inactivation.	0
In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (@DRUG$ or @DRUG$) may result in a significant mutual inactivation.	0
Even when an @DRUG$ and a @DRUG$-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.	1
Even when an @DRUG$ and a penicillin-type drug are administered separately by different routes, a reduction in @DRUG$ serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.	0
Even when an aminoglycoside and a @DRUG$-type drug are administered separately by different routes, a reduction in @DRUG$ serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.	0
There have been isolated reports of patients experiencing increases in their prothrombin times when @DRUG$ was added to @DRUG$ therapy.	4
Elevated plasma levels of @DRUG$ have been reported with concomitant @DRUG$ use.	1
There have been reports of @DRUG$-related side effects in patients on concomitant therapy with @DRUG$ and theophylline.	0
There have been reports of @DRUG$-related side effects in patients on concomitant therapy with quinolones and @DRUG$.	0
There have been reports of theophylline-related side effects in patients on concomitant therapy with @DRUG$ and @DRUG$.	4
Therefore, monitoring of @DRUG$ plasma levels should be considered and dosage of @DRUG$ adjusted, as required.	0
@DRUG$ have been shown to interfere with the metabolism of @DRUG$.	1
@DRUG$, including @DRUG$, may enhance the effects of the oral anticoagulant warfarin or its derivatives.	0
@DRUG$, including nalidixic acid, may enhance the effects of the oral @DRUG$ warfarin or its derivatives.	0
@DRUG$, including nalidixic acid, may enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	4
Quinolones, including @DRUG$, may enhance the effects of the oral @DRUG$ warfarin or its derivatives.	0
Quinolones, including @DRUG$, may enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	4
Quinolones, including nalidixic acid, may enhance the effects of the oral @DRUG$ @DRUG$ or its derivatives.	0
@DRUG$ interferes with the therapeutic action of @DRUG$.	4
@DRUG$ containing @DRUG$, aluminum, or calcium;	0
@DRUG$ containing magnesium, @DRUG$, or calcium;	0
@DRUG$ containing magnesium, aluminum, or @DRUG$;	0
Antacids containing @DRUG$, @DRUG$, or calcium;	0
Antacids containing @DRUG$, aluminum, or @DRUG$;	0
Antacids containing magnesium, @DRUG$, or @DRUG$;	0
@DRUG$ or divalent or trivalent cations such as @DRUG$;	0
@DRUG$ containing @DRUG$;	0
and @DRUG$ , (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.	0
and @DRUG$ , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of @DRUG$, resulting in systemic levels considerably lower than desired.	1
and Videx , (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of @DRUG$, resulting in systemic levels considerably lower than desired.	1
Elevated serum levels of @DRUG$ have been reported with the concomitant use of some @DRUG$ and cyclosporine.	0
Elevated serum levels of @DRUG$ have been reported with the concomitant use of some quinolones and @DRUG$.	0
Elevated serum levels of cyclosporine have been reported with the concomitant use of some @DRUG$ and @DRUG$.	1
Therefore, @DRUG$ serum levels should be monitored and appropriate @DRUG$ dosage adjustments made when these drugs are used concomitantly.	0
@DRUG$ injection and @DRUG$ should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.	3
@DRUG$ should be used with caution, if at all, when potent inhalational @DRUG$ such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.	3
@DRUG$ should be used with caution, if at all, when potent inhalational anesthetics such as @DRUG$ are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.	3
@DRUG$ should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of @DRUG$.	0
ISUPREL should be used with caution, if at all, when potent inhalational @DRUG$ such as @DRUG$ are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.	0
ISUPREL should be used with caution, if at all, when potent inhalational @DRUG$ such as halothane are employed because of potential to sensitize the myocardium to effects of @DRUG$.	0
ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as @DRUG$ are employed because of potential to sensitize the myocardium to effects of @DRUG$.	0
[Dose-time effects of competitive displacement of @DRUG$ by @DRUG$ following oral and intravenous administration];The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	0
[Dose-time effects of competitive displacement of @DRUG$ by sodium perchlorate following oral and intravenous administration];The effect of various doses of s@DRUG$in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	0
[Dose-time effects of competitive displacement of @DRUG$ by sodium perchlorate following oral and intravenous administration];The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of r@DRUG$ in dependence on application mode, was studied. 	0
[Dose-time effects of competitive displacement of radiopertechnetate by @DRUG$ following oral and intravenous administration];The effect of various doses of s@DRUG$in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 	0
[Dose-time effects of competitive displacement of radiopertechnetate by @DRUG$ following oral and intravenous administration];The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of r@DRUG$ in dependence on application mode, was studied. 	0
[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration];The effect of various doses of s@DRUG$in several dose fractions on the extent and the time scale of displacement of r@DRUG$ in dependence on application mode, was studied. 	0
An intravenous dose of 50 mg @DRUG$ was in respect of competitive suppression of organs actively concentrating @DRUG$ as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. 	0
An intravenous dose of 50 mg @DRUG$ was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of @DRUG$. 	0
An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating @DRUG$ as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of @DRUG$. 	0
An intravenous injection of @DRUG$ given later also produces a complete and immediately beginning depletion of @DRUG$ already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels. 	1
Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: @DRUG$;	4
certain @DRUG$, especially the @DRUG$ and polymyxins;	0
certain @DRUG$, especially the aminoglycosides and @DRUG$;	0
certain antibiotics, especially the @DRUG$ and @DRUG$;	0
Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	4
Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	4
Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	4
Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	4
Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	4
Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;procainamide;and quinidine.	4
Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;procainamide;and quinidine.	4
Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;procainamide;and quinidine.	4
Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;@DRUG$;and quinidine.	4
Drugs which may enhance the neuromuscular blocking action of @DRUG$ include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and @DRUG$.	4
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;@DRUG$;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: @DRUG$;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and @DRUG$.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;@DRUG$;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and @DRUG$.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;@DRUG$;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;@DRUG$;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and @DRUG$.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain @DRUG$, especially the @DRUG$ and polymyxins;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;magnesium salts;@DRUG$;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain @DRUG$, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and @DRUG$.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and @DRUG$;lithium;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;@DRUG$;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;@DRUG$ salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;magnesium salts;@DRUG$;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;magnesium salts;procainamide;and @DRUG$.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;@DRUG$;magnesium salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;@DRUG$ salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;@DRUG$;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and @DRUG$;lithium;magnesium salts;procainamide;and @DRUG$.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;@DRUG$ salts;procainamide;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;@DRUG$;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;@DRUG$;magnesium salts;procainamide;and @DRUG$.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;@DRUG$;and quinidine.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;@DRUG$ salts;procainamide;and @DRUG$.	0
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;@DRUG$;and @DRUG$.	0
The prior administration of @DRUG$ does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by @DRUG$.	4
@DRUG$ should not be administered until a patient has recovered from @DRUG$-induced neuromuscular block.	3
Although the pressor activity of @DRUG$ is very low compared to its antidiuretic activity, large doses of @DRUG$ Tablets should be used with other pressor agents only with careful patient monitoring.	0
@DRUG$: In three pharmacokinetic studies including 46 normal, healthy subjects, @DRUG$ clearance and concentration were not significantly altered by the addition of lomefloxacin.	0
@DRUG$: In three pharmacokinetic studies including 46 normal, healthy subjects, theophylline clearance and concentration were not significantly altered by the addition of @DRUG$.	0
Theophylline: In three pharmacokinetic studies including 46 normal, healthy subjects, @DRUG$ clearance and concentration were not significantly altered by the addition of @DRUG$.	0
In clinical studies where patients were on chronic @DRUG$ therapy, @DRUG$ had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.	0
In clinical studies where patients were on chronic @DRUG$ therapy, lomefloxacin had no measurable effect on the mean distribution of @DRUG$ concentrations or the mean estimates of theophylline clearance.	0
In clinical studies where patients were on chronic @DRUG$ therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of @DRUG$ clearance.	0
In clinical studies where patients were on chronic theophylline therapy, @DRUG$ had no measurable effect on the mean distribution of @DRUG$ concentrations or the mean estimates of theophylline clearance.	0
In clinical studies where patients were on chronic theophylline therapy, @DRUG$ had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of @DRUG$ clearance.	0
In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of @DRUG$ concentrations or the mean estimates of @DRUG$ clearance.	0
@DRUG$ and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
@DRUG$ and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
@DRUG$ and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
@DRUG$ and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	0
Antacids and @DRUG$: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and @DRUG$: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and @DRUG$: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and @DRUG$: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	0
Antacids and sucralfate: @DRUG$ and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: @DRUG$ and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: @DRUG$ and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	1
Antacids and sucralfate: Sucralfate and @DRUG$ containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	0
Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	1
Antacids and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	1
Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	0
Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	1
Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	1
@DRUG$ administered 2 hours before @DRUG$ resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).	1
@DRUG$- and @DRUG$-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.	0
@DRUG$- and aluminum-containing @DRUG$, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.	0
@DRUG$- and aluminum-containing antacids, administered concomitantly with @DRUG$, significantly decreased the bioavailability (48%) of lomefloxacin.	1
@DRUG$- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of @DRUG$.	0
Magnesium- and @DRUG$-containing @DRUG$, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.	0
Magnesium- and @DRUG$-containing antacids, administered concomitantly with @DRUG$, significantly decreased the bioavailability (48%) of lomefloxacin.	1
Magnesium- and @DRUG$-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of @DRUG$.	0
Magnesium- and aluminum-containing @DRUG$, administered concomitantly with @DRUG$, significantly decreased the bioavailability (48%) of lomefloxacin.	1
Magnesium- and aluminum-containing @DRUG$, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of @DRUG$.	0
Magnesium- and aluminum-containing antacids, administered concomitantly with @DRUG$, significantly decreased the bioavailability (48%) of @DRUG$.	0
Separating the doses of @DRUG$ and @DRUG$ minimizes this decrease in bioavailability;	1
therefore, administration of these agents should precede @DRUG$ dosing by 4 hours or follow @DRUG$ dosing by at least 2 hours.	0
@DRUG$: Two hundred mg of @DRUG$ (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of lomefloxacin after being dosed at 400 mg qd.	0
@DRUG$: Two hundred mg of caffeine (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of @DRUG$ after being dosed at 400 mg qd.	0
Caffeine: Two hundred mg of @DRUG$ (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of @DRUG$ after being dosed at 400 mg qd.	0
This did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either @DRUG$ or its major metabolite, @DRUG$.	0
Other @DRUG$ have demonstrated moderate to marked interference with the metabolism of @DRUG$, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.	1
Other @DRUG$ have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of @DRUG$.	0
Other quinolones have demonstrated moderate to marked interference with the metabolism of @DRUG$, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of @DRUG$.	0
@DRUG$: @DRUG$ has been demonstrated to interfere with the elimination of other quinolones.	0
@DRUG$: Cimetidine has been demonstrated to interfere with the elimination of other @DRUG$.	0
Cimetidine: @DRUG$ has been demonstrated to interfere with the elimination of other @DRUG$.	1
The interaction between @DRUG$ and @DRUG$ has not been studied.	0
@DRUG$: Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with other members of the quinolone class.	0
@DRUG$: Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with other members of the quinolone class.	0
@DRUG$: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the @DRUG$.	0
Cyclosporine: Elevated serum levels of @DRUG$ have been reported with concomitant use of @DRUG$ with other members of the quinolone class.	0
Cyclosporine: Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with other members of the @DRUG$.	0
Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with other members of the @DRUG$.	1
Interaction between @DRUG$ and @DRUG$ has not been studied.	0
@DRUG$: No clinically significant changes in @DRUG$ pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.	0
@DRUG$: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of @DRUG$ 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.	0
@DRUG$: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of @DRUG$ (20 mg qd) in 13 healthy volunteers.	0
Omeprazole: No clinically significant changes in @DRUG$ pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of @DRUG$ 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.	0
Omeprazole: No clinically significant changes in @DRUG$ pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of @DRUG$ (20 mg qd) in 13 healthy volunteers.	0
Omeprazole: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of @DRUG$ 400 mg was given after multiple doses of @DRUG$ (20 mg qd) in 13 healthy volunteers.	0
@DRUG$: No significant differences were observed in mean @DRUG$ AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.	0
@DRUG$: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended @DRUG$ capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.	0
@DRUG$: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with @DRUG$ (400 mg qd) for five days in 15 healthy males.	0
Phenytoin: No significant differences were observed in mean @DRUG$ AUC, C max , C min or T max (although C max increased by 11%) when extended @DRUG$ capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.	0
Phenytoin: No significant differences were observed in mean @DRUG$ AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with @DRUG$ (400 mg qd) for five days in 15 healthy males.	0
Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended @DRUG$ capsules (100 mg tid) were coadministered with @DRUG$ (400 mg qd) for five days in 15 healthy males.	0
@DRUG$ is unlikely to have a significant effect on @DRUG$ metabolism.	0
@DRUG$: @DRUG$ slows the renal elimination of lome-floxacin.	0
@DRUG$: No clinically significant changes occurred in heart rate or corrected QT intervals, or in @DRUG$ metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.	0
@DRUG$: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or @DRUG$ pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.	0
@DRUG$: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of @DRUG$ and terfenadine at steady-state in 28 healthy males.	0
@DRUG$: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and @DRUG$ at steady-state in 28 healthy males.	0
Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in @DRUG$ metabolite or @DRUG$ pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.	0
Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in @DRUG$ metabolite or lomefloxacin pharmacokinetics, during concurrent administration of @DRUG$ and terfenadine at steady-state in 28 healthy males.	0
Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in @DRUG$ metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and @DRUG$ at steady-state in 28 healthy males.	0
Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or @DRUG$ pharmacokinetics, during concurrent administration of @DRUG$ and terfenadine at steady-state in 28 healthy males.	0
Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or @DRUG$ pharmacokinetics, during concurrent administration of lomefloxacin and @DRUG$ at steady-state in 28 healthy males.	0
Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of @DRUG$ and @DRUG$ at steady-state in 28 healthy males.	0
@DRUG$: @DRUG$ may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.	0
@DRUG$: Quinolones may enhance the effects of the oral @DRUG$, warfarin, or its derivatives.	0
@DRUG$: Quinolones may enhance the effects of the oral anticoagulant, @DRUG$, or its derivatives.	0
Warfarin: @DRUG$ may enhance the effects of the oral @DRUG$, warfarin, or its derivatives.	4
Warfarin: @DRUG$ may enhance the effects of the oral anticoagulant, @DRUG$, or its derivatives.	4
Warfarin: Quinolones may enhance the effects of the oral @DRUG$, @DRUG$, or its derivatives.	0
However, no clinically or statistically significant differences in prothrombin time ratio or @DRUG$ enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both @DRUG$ and lomefloxacin under steady-state conditions.	0
However, no clinically or statistically significant differences in prothrombin time ratio or @DRUG$ enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both warfarin and @DRUG$ under steady-state conditions.	0
However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both @DRUG$ and @DRUG$ under steady-state conditions.	0
Additive CNS depression may occur when @DRUG$ are administered concomitantly with other @DRUG$ including barbiturates, tranquilizers, and alcohol.	4
Additive CNS depression may occur when @DRUG$ are administered concomitantly with other CNS depressants including @DRUG$, tranquilizers, and alcohol.	4
Additive CNS depression may occur when @DRUG$ are administered concomitantly with other CNS depressants including barbiturates, @DRUG$, and alcohol.	4
Additive CNS depression may occur when @DRUG$ are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and @DRUG$.	4
Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including @DRUG$, tranquilizers, and alcohol.	0
Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including barbiturates, @DRUG$, and alcohol.	0
Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including barbiturates, tranquilizers, and @DRUG$.	0
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including @DRUG$, @DRUG$, and alcohol.	0
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including @DRUG$, tranquilizers, and @DRUG$.	0
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, @DRUG$, and @DRUG$.	0
Patients receiving @DRUG$ should be advised against the concurrent use of other @DRUG$.	3
@DRUG$ prolong and intensify the anticholinergic effects of @DRUG$.	4
After multiple dosing, @DRUG$ (@DRUG$  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.	0
After multiple dosing, @DRUG$ (AVONEX  30 mcg IM once weekly) reduced @DRUG$  clearance by approximately 30%.	1
After multiple dosing, interferon beta-1a (@DRUG$  30 mcg IM once weekly) reduced @DRUG$  clearance by approximately 30%.	1
The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	0
The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	0
The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	0
The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	0
The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	0
The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	0
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	0
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	0
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	0
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	0
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	0
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	0
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	0
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	0
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	0
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	0
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	0
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	0
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	0
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	0
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or @DRUG$.	0
@DRUG$: Since @DRUG$ is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.	0
@DRUG$: Since heparin is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.	0
@DRUG$: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of @DRUG$ and heparin is unlikely for this indication.	0
@DRUG$: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and @DRUG$ is unlikely for this indication.	0
Heparin: Since @DRUG$ is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.	0
Heparin: Since @DRUG$ is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of @DRUG$ and heparin is unlikely for this indication.	0
Heparin: Since @DRUG$ is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and @DRUG$ is unlikely for this indication.	0
Heparin: Since heparin is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of @DRUG$ and heparin is unlikely for this indication.	0
Heparin: Since heparin is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of Argatroban and @DRUG$ is unlikely for this indication.	0
Heparin: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of @DRUG$ and @DRUG$ is unlikely for this indication.	0
However, if @DRUG$ is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.	0
However, if @DRUG$ is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	0
However, if Argatroban is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	0
@DRUG$/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	0
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	0
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	0
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	0
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	0
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	0
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	0
Oral @DRUG$: Pharmacokinetic drug-drug interactions between @DRUG$ and warfarin (7.5 mg single oral dose) have not been demonstrated.	0
Oral @DRUG$: Pharmacokinetic drug-drug interactions between Argatroban and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	0
Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between @DRUG$ and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	0
However, the concomitant use of @DRUG$ and @DRUG$ (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).	4
@DRUG$: The safety and effectiveness of @DRUG$ with thrombolytic agents have not been established.	0
@DRUG$: The safety and effectiveness of Argatroban with @DRUG$ have not been established.	0
Thrombolytic agents: The safety and effectiveness of @DRUG$ with @DRUG$ have not been established.	0
Co-administration: Concomitant use of @DRUG$ with @DRUG$, thrombolytics, and other anticoagulants may increase the risk of bleeding.	4
Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, @DRUG$, and other anticoagulants may increase the risk of bleeding.	4
Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	4
Co-administration: Concomitant use of Argatroban with @DRUG$, @DRUG$, and other anticoagulants may increase the risk of bleeding.	0
Co-administration: Concomitant use of Argatroban with @DRUG$, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	0
Co-administration: Concomitant use of Argatroban with antiplatelet agents, @DRUG$, and other @DRUG$ may increase the risk of bleeding.	0
Drug-drug interactions have not been observed between @DRUG$ and @DRUG$ or erythromycin.	0
Drug-drug interactions have not been observed between @DRUG$ and digoxin or @DRUG$.	0
Drug-drug interactions have not been observed between Argatroban and @DRUG$ or @DRUG$.	0
The effects of @DRUG$ and of @DRUG$ anesthesia on digitalis tolerance in dogs.  	0
The effects of @DRUG$ and of Innovar anesthesia on @DRUG$ tolerance in dogs.  	0
The effects of ketamine and of @DRUG$ anesthesia on @DRUG$ tolerance in dogs.  	0
In a comparison of @DRUG$ tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	0
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	0
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	0
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	0
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital. 	0
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital. 	0
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital. 	0
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$. 	0
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	4
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	4
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 	4
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with @DRUG$ or Innovar than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or @DRUG$ than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with @DRUG$. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or @DRUG$ than with pentobarbital. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with @DRUG$. 	0
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with @DRUG$. 	0
Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	4
Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or droperidol but not after administration of fentayl alone or after pentobarbital.	4
Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, ketamine, or @DRUG$ but not after administration of fentayl alone or after pentobarbital.	4
Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of @DRUG$ alone or after pentobarbital.	0
Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after @DRUG$.	0
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, @DRUG$, or droperidol but not after administration of fentayl alone or after pentobarbital.	0
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or @DRUG$ but not after administration of fentayl alone or after pentobarbital.	0
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or droperidol but not after administration of @DRUG$ alone or after pentobarbital.	0
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or droperidol but not after administration of fentayl alone or after @DRUG$.	0
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or @DRUG$ but not after administration of fentayl alone or after pentobarbital.	0
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or droperidol but not after administration of @DRUG$ alone or after pentobarbital.	0
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or droperidol but not after administration of fentayl alone or after @DRUG$.	0
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or @DRUG$ but not after administration of @DRUG$ alone or after pentobarbital.	0
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or @DRUG$ but not after administration of fentayl alone or after @DRUG$.	0
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of @DRUG$ alone or after @DRUG$.	0
Interaction on the antinociceptive effect between @DRUG$ and @DRUG$ or tuftsin.  	4
Interaction on the antinociceptive effect between @DRUG$ and enkephalins or @DRUG$.  	4
Interaction on the antinociceptive effect between neurotensin and @DRUG$ or @DRUG$.  	0
The aim of this paper was to study the interaction between @DRUG$ and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	0
The aim of this paper was to study the interaction between @DRUG$ and both enkephalins or its synthetic analogue @DRUG$, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	0
The aim of this paper was to study the interaction between @DRUG$ and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	0
The aim of this paper was to study the interaction between neurotensin and both @DRUG$ or its synthetic analogue @DRUG$, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	0
The aim of this paper was to study the interaction between neurotensin and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	0
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue @DRUG$, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 	0
It was shown that @DRUG$ antagonized evidently the antinociceptive effect of @DRUG$ and their analogue. 	4
On the contrary, @DRUG$ and @DRUG$ were agonists in induction of analgesia. 	4
It is concluded that @DRUG$ modulates in an opposite way the function of the enkephalinergic neurons and the central action of @DRUG$.	4
@DRUG$, a @DRUG$, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.	0
@DRUG$, a cytostatic agent, has been reported to inactivate the antifungal activity of @DRUG$ by competitive inhibition.	4
Cytosine arabinoside, a @DRUG$, has been reported to inactivate the antifungal activity of @DRUG$ by competitive inhibition.	0
Urinary acidifying agents These agents (@DRUG$, @DRUG$, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	0
Urinary acidifying agents These agents (@DRUG$, sodium acid phosphate, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	1
Urinary acidifying agents These agents (ammonium chloride, @DRUG$, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	1
@DRUG$ @DRUG$ are inhibited by amphetamines.	0
@DRUG$ Adrenergic blockers are inhibited by @DRUG$.	0
Adrenergic blockers @DRUG$ are inhibited by @DRUG$.	4
@DRUG$, @DRUG$ Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	0
@DRUG$, tricyclic @DRUG$ may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	0
@DRUG$, tricyclic Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	0
@DRUG$, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or @DRUG$;	0
Antidepressants, @DRUG$ @DRUG$ may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	0
Antidepressants, @DRUG$ Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	0
Antidepressants, @DRUG$ Amphetamines may enhance the activity of tricyclic antidepressants or @DRUG$;	0
Antidepressants, tricyclic @DRUG$ may enhance the activity of @DRUG$ or sympathomimetic agents;	4
Antidepressants, tricyclic @DRUG$ may enhance the activity of tricyclic antidepressants or @DRUG$;	4
Antidepressants, tricyclic Amphetamines may enhance the activity of @DRUG$ or @DRUG$;	0
@DRUG$ with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	1
@DRUG$ with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	1
@DRUG$ with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	1
@DRUG$ with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	0
d-amphetamine with @DRUG$ or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	0
d-amphetamine with @DRUG$ or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	0
d-amphetamine with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	0
d-amphetamine with desipramine or @DRUG$ and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	0
d-amphetamine with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	0
d-amphetamine with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of @DRUG$ in the brain;	0
@DRUG$ @DRUG$, as well as a metabolite of furazolidone, slow amphetamine metabolism.	0
@DRUG$ MAOI antidepressants, as well as a metabolite of @DRUG$, slow amphetamine metabolism.	0
@DRUG$ MAOI antidepressants, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.	0
MAO inhibitors @DRUG$, as well as a metabolite of @DRUG$, slow amphetamine metabolism.	0
MAO inhibitors @DRUG$, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.	1
MAO inhibitors MAOI antidepressants, as well as a metabolite of @DRUG$, slow @DRUG$ metabolism.	1
@DRUG$: @DRUG$ may counteract the sedative effect of antihistamines.	0
@DRUG$: Amphetamines may counteract the sedative effect of @DRUG$.	0
Antihistamines: @DRUG$ may counteract the sedative effect of @DRUG$.	4
@DRUG$: @DRUG$ may antagonize the hypotensive effects of antihypertensives.	0
@DRUG$: Amphetamines may antagonize the hypotensive effects of @DRUG$.	0
Antihypertensives: @DRUG$ may antagonize the hypotensive effects of @DRUG$.	4
@DRUG$: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.	0
@DRUG$: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat amphetamine poisoning.	0
@DRUG$: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat @DRUG$ poisoning.	0
Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat amphetamine poisoning.	4
Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat @DRUG$ poisoning.	0
Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat @DRUG$ poisoning.	0
@DRUG$: @DRUG$ may delay intestinal absorption of ethosuximide.	0
@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$.	0
Ethosuximide: @DRUG$ may delay intestinal absorption of @DRUG$.	1
@DRUG$: @DRUG$ blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.	0
@DRUG$: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of @DRUG$.	0
Haloperidol: @DRUG$ blocks dopamine receptors, thus inhibiting the central stimulant effects of @DRUG$.	4
@DRUG$: The anorectic and stimulatory effects of @DRUG$ may be inhibited by lithium carbonate.	0
@DRUG$: The anorectic and stimulatory effects of amphetamines may be inhibited by @DRUG$.	0
Lithium carbonate: The anorectic and stimulatory effects of @DRUG$ may be inhibited by @DRUG$.	4
@DRUG$: @DRUG$ potentiate the analgesic effect of meperidine.	0
@DRUG$: Amphetamines potentiate the analgesic effect of @DRUG$.	0
Meperidine: @DRUG$ potentiate the analgesic effect of @DRUG$.	4
@DRUG$ therapy Urinary excretion of @DRUG$ is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.	0
@DRUG$ therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in @DRUG$ therapy.	0
Methenamine therapy Urinary excretion of @DRUG$ is increased, and efficacy is reduced by acidifying agents used in @DRUG$ therapy.	1
@DRUG$: @DRUG$ enhance the adrenergic effect of norepinephrine.	0
@DRUG$: Amphetamines enhance the adrenergic effect of @DRUG$.	0
Norepinephrine: @DRUG$ enhance the adrenergic effect of @DRUG$.	4
@DRUG$: @DRUG$ may delay intestinal absorption of phenobarbital;	0
@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;	0
Phenobarbital: @DRUG$ may delay intestinal absorption of @DRUG$;	1
@DRUG$: @DRUG$ may delay intestinal absorption of phenytoin;	0
@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;	0
Phenytoin: @DRUG$ may delay intestinal absorption of @DRUG$;	1
@DRUG$: In cases of @DRUG$ overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.	0
@DRUG$: In cases of propoxyphene overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.	0
Propoxyphene: In cases of @DRUG$ overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.	4
@DRUG$: @DRUG$ inhibit the hypotensive effect of veratrum alkaloids.	0
@DRUG$: Amphetamines inhibit the hypotensive effect of @DRUG$.	0
Veratrum alkaloids: @DRUG$ inhibit the hypotensive effect of @DRUG$.	4
